CBDWire – InvestorBrandNetwork (IBN) Content Platform

Lexaria Bioscience Corp. (NASDAQ: LEXX) Building a Global Presence with Superior Delivery Technology for Wide Range of Drugs and Active Pharmaceutical Ingredients

December 1, 2023

December 1, 2023 08:05:00

Lexaria, a global innovator in drug delivery platforms, has, through its patented DehydraTECH(TM) technology, proven to enhance the performance of several categories of fat-soluble active molecules and drugs
Since 2018, human clinical studies on the technology have yielded positive results, ultimately earning Lexaria 37 granted patents globally, with many more pending around the world
With the strides made so far, Lexaria looks to grow its revenue and commercial opportunities through licensing

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains committed to its mission to provide healthier delivery methods of drugs and other Active Pharmaceutical Ingredients (“APIs”). This is made possible through its patented drug delivery technology, DehydraTECH(TM), proven to enhance the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats.

The company’s efforts have focused on several key segments, including hypertension, diabetes, antivirals, epilepsy, nicotine replacement, and more. This has been an ongoing process since 2016, with positive results achieved from various clinical studies thus far, showing up to 17x brain absorption improvements…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled recognition and brand awareness.

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Generate Sizable License Revenue from IP Growth, Expanding Patent Suite

November 20, 2023

November 20, 2023 09:35:00

Lexaria, a global innovator in drug delivery platforms, has, since 2014, continuously worked on its patented DehydraTECH(TM) drug delivery technology
The technology has demonstrated overall effectiveness in enhanced delivery of fat-soluble molecules through the human gastrointestinal system, as affirmed by clinical testing
This overall effectiveness and push for its development has earned Lexaria 37 granted patents globally, with many patents pending
The company is constantly enhancing its patent portfolio, since granted patents can support an increase in licensing revenue

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is eyeing growth in license revenue from its intellectual property (“IP”). Since 2014, the company has continuously worked on its flagship technology – the patented DehydraTECH(TM) drug delivery technology – which has demonstrated the improvement of speed of onset, brain absorption, and bioavailability (https://cnw.fm/HZKIV). It is being investigated in association with dementia treatment, nicotine replacement, hypertension, and heart disease treatment, among other applications (https://cnw.fm/y5ECe).

So far, Lexaria has received 37 granted patents globally, with many patents pending. The company is aggressively pushing its patent application process as it recognizes the viable commercial application of its flagship technology. In addition, the company understands that successfully granted patents can lead…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Patented DehydraTECH(TM) Technology’s Effectiveness on GLP-1 Drugs for Potential Diabetes Treatment and Weight Loss

November 8, 2023

November 8, 2023 08:05:00

Lexaria, a global innovator in drug delivery platforms, recently announced plans to launch new human and animal studies examining whether its patented DehydraTECH(TM) technology can make GLP-1 drugs better
Lexaria has previously demonstrated DehydraTECH’s overall potential in its DIAB-A22-1 animal study, which yielded weight loss, and improved triglyceride and cholesterol levels among diabetic-conditioned animals
The company plans to replicate the results from this study while also exploring ways to improve the overall bioavailability of GLP-1 drugs for diabetes treatment and weight loss
Lexaria management is optimistic that it will build on previous studies, replicate previous positive results, and improve the overall efficacy of GLP-1 drugs

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced plans to launch new human and animal studies that seek to examine its patented DehydraTECH(TM) technology’s potential on GLP-1 drugs for the treatment of diabetes and weight loss. This announcement follows the recent study results published on “New England Journal of Medicine,” which showed that 49 to 52 pounds weight loss was a common outcome across the 2,539 adult study participants (https://cnw.fm/bP9IJ).

DehydraTECH has demonstrated, in many instances, significant improvement in how active pharmaceutical ingredients (“APIs”) enter the bloodstream with its strong bioavailability enhancing capabilities. Its unique and revolutionary approach has seen Lexaria granted 37 patents for the…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows List of Licensed Partners Following Exclusive Collaboration and License Agreement with SulfoSyn

October 31, 2023

October 31, 2023 08:05:00

Lexaria, a global innovator in drug delivery platforms, just announced an exclusive license to SulfoSyn Limited to use its patented DehydraTECH(TM) technology
Lexaria will also perform specific DehydraTECH-related manufacturing operations on SulfoSyn’s behalf for an initial term of 2 years
The license agreement adds to Lexaria’s growing list, which, as of the last two years, includes BevNology LLC, Premier Wellness Science Co. Ltd., and Dehydr8, LLC, among others
It highlights the superiority of Lexaria’s technology, as further compounded by the 37 patents granted so far

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its latest global, exclusive license to SulfoSyn Limited to use its patented DehydraTECH(TM) technology. This license will allow SulfoSyn to use Lexaria’s technology in non-pharmaceutical uses of sulforaphane worldwide, with the ability to sub-license its rights to other companies (https://cnw.fm/O8yxc).

This agreement is the product of months of research for the two entities. In late 2022, both Lexaria and SulfoSyn started exploring the applicability of DehydraTECH upon sulforaphane. This Sulphur-rich composite molecule is commonly found in vegetables such as broccoli, kale, and…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Two New Canadian Patents Amid Continued Efforts to Safeguard the Applicability of Its DehydraTECH(TM) Technology in Multiple Jurisdictions and Sectors

October 26, 2023

October 26, 2023 08:05:00

Lexaria has continuously taken steps to protect its intellectual property internationally to safeguard the applicability of its patented DehydraTECH(TM) technology across the globe
The company recently announced that it had received two new Canadian patents, increasing to 37 the number of granted patents in its intellectual property (“IP”) portfolio
Lexaria has filed tens of patent applications in multiple jurisdictions that are considered to have the highest commercial potential
The company continues to investigate opportunities that could culminate in expansions of and additions to its intellectual property portfolio and is also filing new patent applications for discoveries that arise from its R&D programs

Lexaria Bioscience (NASDAQ: LEXX) is a global innovator and biotechnology company focused on developing technology that enhances the bioavailability of multiple fat-soluble active molecules and active pharmaceutical ingredients (“APIs”). The company’s flagship technology is the patented DehydraTECH(TM) drug delivery technology, which combines fat-soluble (lipophilic) molecules or APIs with specific fatty acids and carrier compounds, improving properties such as the speed of onset, brain absorption, and bioavailability.

The company has continuously worked on DehydraTECH since 2014, with these efforts expanding the technology’s potential area of impact, both geographically and by sector. For instance, thanks to its extensive research and development (“R&D”), the company has identified viable commercial…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Raised $1.6 Million in Latest Investment Round; Looks to Advance DehydraTECH(TM) Research Operations

October 19, 2023

October 19, 2023 08:35:00

Lexaria, a global innovator in drug delivery platforms, recently announced that it had entered into a securities purchase agreement with a single health-focused institutional investor
The agreement is for the purchase of 1,618,330 shares of common stock at $0.97 per share, with gross proceeds amounting to approximately $1.6 million
The raised funds will be integral to Lexaria advancing its operations, inching it closer to FDA approval for its patented DehydraTECH(TM)-processed CBD for the potential treatment of hypertension
It will also help assert Lexaria’s position as a leader in the market, even as it pushes the envelope in terms of research and development of its revolutionary DehydraTECH technology

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, raised approximately $1.6 million from its latest round of investment in what will mark a significant milestone for the company. In September 2023, the company announced that it had entered into a securities purchase agreement with a single healthcare-focused institutional investor to purchase 1,618,330 shares of common stock at $0.97 per share. Maxim Group LLC acted as the sole placement agent in connection with the offering (https://cnw.fm/TNjLB).

The warrants will become exercisable six months from issuance, expiring five and a half years from the issuance date. These shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-262402), declared effective by the…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Ongoing Diabetes Study Program to Examine its Patented DehydraTECH(TM) Technology with Launch of Human and Animal Studies for Oral GLP-1 Drugs

October 16, 2023

October 16, 2023 08:50:00

Lexaria recently announced its intention to launch new human and animal studies exploring its patented DehydraTECH(TM) technology on GLP-1 drugs for the potential treatment of diabetes
The studies will build on what Lexaria has achieved so far since it started its diabetes-related studies in 2022
Its DehydraTECH-CBD demonstrated an almost three-fold improvement in drug delivery into the blood in its DIAB-A22-1 diabetes study compared to the DehydraTECH-CBD formulation used in its HYPER-H21-4 hypertension study
These studies follow Lexaria’s announcement of its intention to study weight loss and diabetes control in a human population using DehydraTECH

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its intention to launch new human and animal studies that will explore its patented DehydraTECH(TM) technology on glucagon-like peptide-1 (“GLP-1”) drugs for improved bioavailability, cost-effectiveness, tolerability, weight loss potential, management of diabetes and other health conditions. Regarded as a significant expansion for Lexaria, these studies will build on what the company has achieved so far with its DehydraTECH-processed CBD while examining the technology’s impact on GLP-1 drugs (https://cnw.fm/Np3FA).

The U.S. Food and Drug Administration (“FDA”) recently approved GLP-1 drugs for type 2 diabetes and weight loss management following their demonstration of an average loss of 15% of body weight across 667 individuals in a 68-week-long study. The drug has also demonstrated that some patients experience…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Steadily Advancing its DehydraTECH(TM) Technology, Having Demonstrated its Potential Across Multiple Areas of Application

September 29, 2023

September 29, 2023 08:50:00

Lexaria’s patented DehydraTECH(TM)-processed CBD has shown its ability to lower blood pressure in patients over multiple weeks
This technology has also shown positive impacts in obese diabetic-conditioned animals from its DIAB-A22-1 pre-clinical study
The NIC-H22-1 human nicotine study also demonstrated a statistically significant difference to achieve maximum blood saturation
These results have demonstrated DehydraTECH’s potential while propping it to take advantage of vastly untapped markets with potential for growth in the coming years

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is steadily advancing its patented DehydraTECH(TM) technology for its growing range of applications, which include oral nicotine, hypertension, antivirals, human hormone therapy, diabetes and more. The progress achieved thus far has been the product of years of clinical and pre-clinical research, all of which reflect management’s confidence in the company’s direction and technology.

As of the three months ended May 31, 2023, the company had increased its research and development (“R&D”) expenses by 118% year-over-year, primarily focused on the execution of hypertension, oral nicotine, and diabetes studies (https://cnw.fm/WUofP). This devotion of a significant proportion of its…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) to Demonstrate DehydraTECH-CBD Benefits in Upcoming Investigational New Drug Application Submission

September 21, 2023

September 21, 2023 08:05:00

Lexaria’s IND application builds on five previous human clinical studies showing zero serious adverse effects and evidencing a reduction in resting blood pressure in test subjects
DehydraTECH(TM)-CBD has the potential to have pronounced clinical benefits relative to the available anti-hypertensive therapeutics on the market today
Work mostly under Lexaria’s control was completed earlier this year, including the batch manufacturing of DehydraTECH-CBD and placebo materials necessary for the IND application
Lexaria is waiting to submit until the necessary documentation outside of their control is ready for the IND application

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains on track for its upcoming Investigational New Drug (“IND”) submission. The application is for the company’s planned US Phase 1b Hypertension Clinical Trial HYPER-H23-1, entitled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” looks to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM)-processed CBD in hypertensive patients.

Lexaria’s IND submission builds on five previous human clinical studies conducted from 2018 to 2022 and is integral to the successful filing and review of the submission. These studies were carried out in an aggregate total of 134 healthy and hypertensive persons and evidenced significant reductions in…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) is On Track for IND Application with the FDA for its Planned U.S. Phase 1b Hypertension Clinical Trial

September 15, 2023

September 15, 2023 08:05:00

Lexaria’s IND application for its U.S. Phase 1b Hypertension Clinical Study, HYPER-H23-1, remains on track despite setbacks
Work mostly under Lexaria’s control was completed earlier this year, while work that is outside its control remains delayed
Regardless, Lexaria continues to make progress, even as it looks to take advantage of the growing global cardiovascular drugs market, which is projected to post a CAGR of 3.1% between 2021 and 2026
Chris Bunka, Lexaria’s CEO, has lauded the company’s exceptional discovery, which demonstrates the ability of the patented DehydraTECH-processed CBD to lower blood pressure in the patient population

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains on track for its upcoming submission of an Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial, dubbed HYPER-H23-1. The study, entitled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” looks to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM)-processed CBD in hypertensive patients (https://cnw.fm/8q5JV).

This study builds on five previous human clinical studies conducted from 2018 to 2022, which will be integral to the successful filing and review of the planned IND submission. Most notably, the studies, which involved 134 healthy and hypertensive persons, evidenced significant reductions in resting…

Read M o re>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is powered by IBN

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Investigational Research Programs Position the Company for Important Partnership Opportunities and Growth

September 12, 2023

September 12, 2023 08:05:00

Lexaria Bioscience has completed several studies that confirm and support the superiority and advantages of its patented DehydraTECH(TM) technology over traditional oral delivery methods
The company recently announced results from its human oral nicotine study NIC-H22-1 comparing its DehydraTECH-nicotine pouch to world-leading brands, Zyn(R) and on!(R)
Results from the study demonstrated that DehydraTECH-nicotine was statistically significantly faster in reaching Tmax than both brands
Lexaria has also undertaken other investigational research programs, including the analysis and execution of hypertension, diabetes, hormone therapy, and dementia studies, which could birth excellent partnership opportunities, supporting further growth
A report by Zacks Investment Research discussed the nicotine study alongside Lexaria’s other recent milestones, maintaining a $12.00 price target

Lexaria Bioscience (NASDAQ: LEXX), a global innovator seeking to enhance the bioavailability of multiple active pharmaceutical ingredients using its patented DehydraTECH(TM) drug delivery technology platform, continues to devote an increasing proportion of its resources and focus toward research and development (“R&D”) as part of its overall goal to establish areas of investigation for commercial pursuits and reduce risks of the unknown for both commercial and regulatory goals.

In the three months ended May 31, 2023 (“Q3 2023”), for example, the company increased its R&D expenses 118% year over year to $1.64 million in Q3 2023 from $752,095 in Q3 2022, with a recent Zacks Investment Research report attributing this expenditure to Lexaria’s multiple…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is powered by IBN

CBDNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) ‘Strategically Important’ Patent Grants Protection in One of World’s Leading Oral Nicotine Markets

September 8, 2023

September 8, 2023 11:29:21

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently celebrated the receipt of U.S. patent #11,700,875, titled “Compositions and Methods For Sublingual Delivery of Nicotine.” The patent covers various forms and sources of nicotine, including nicotine benzoate, nicotine polacrilex, nicotine citrate, nicotine detartrate, and many others, for use in sublingual delivery formats like oral pouches. “The new U.S. patent is remarkable and ‘strategically important’ in many ways. First, it is the company’s 35th overall granted patent worldwide and the 13th granted in the United States. Second, a total of 30 claims were awarded within this patent, the highest number of claims accepted by the USPTO in the company’s existing portfolio. And with researchers agreeing that patents with a higher number of claims are better protected and can be an important measure of value, the claims increase the value of the new patent and perhaps even the company’s entire IP portfolio,” a recent article reads. “Third… the new U.S. patent could lead to the award of patents within this family in other countries… Moreover, the new patent grants IP protection within the United States, one of the world’s leading oral nicotine markets, according to an analysis by the Foundation for a Smoke-Free World. The U.S. nicotine pouches market is projected to grow at a 33% CAGR between 2023 and 2030.”

To view the full article, visit https://cnw.fm/ymT0t

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 35 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes What Is Considered One Of America’s Most Serious Health Problems

September 1, 2023

September 1, 2023 08:50:00

The ADA reports that 37.3 million Americans had diabetes in 2019, and the number has been growing by an average 1.4 million each year
95% of Americans with diabetes are diagnosed with type 2 diabetes, which can lead to heart disease, stroke, kidney damage, and nerve damage when left untreated
Lexaria’s DIAB-A22-1 pre-clinical diabetes study using DehydraTECH(TM)-CBD in obese diabetic-conditioned animals shows promising results, prompting the company to investigate for human trial

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced its intent to conduct a human clinical trial to examine its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for diabetes control and weight loss. The company’s pre-clinical diabetes study, DIAB-A22-1, in obese diabetic-conditioned animals, provided successful results and has driven Lexaria’s management to investigate whether animal improvements will be evidenced in humans.

Diabetes can impact various parts of the body, including the heart, kidneys, eyes, feet, and legs. The longer a person lives with the condition at high blood sugar levels, the more serious complications can…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Strategic Updates Concerning Patented DehydraTECH(TM) Technology

August 21, 2023

August 21, 2023 09:35:00

Lexaria’s human oral nicotine study, NIC-H22-1, comparing world-leading brands and the company’s DehydraTECH(TM)-Nicotine tobacco-free pouch, reported positive results, including higher pleasurable effects and reduced negative effects
A new patent has been granted to Lexaria and is strategically important to the company’s oral nicotine sector research and development efforts
Lexaria continues to research diabetes control and weight loss with its DehydraTECH(TM)-CBD, announcing favorable animal study results and the intent to develop a human clinical study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced updates regarding its patented DehydraTECH(TM) technology – which improves the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. Lexaria’s primary focus for DehydraTECH research and development includes advancements of product candidates across key segments, including nicotine replacement, diabetes control and weight loss, and hypertension.

The company’s most recent announcement reported results from its 2023 human oral nicotine study NIC-H22-1, comparing Lexaria’s DehydraTECH(TM)-Nicotine tobacco-free pouch to world-leading brands ZYN(R) and on!. Using measurements to determine the median time required to reach comparable…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Intent for Human Clinical Study for Diabetes and Weight Loss Following Positive DehydraTECH(TM)-CBD Results in Animals

August 10, 2023

August 10, 2023 08:05:00

Lexaria’s patented DehydraTECH(TM)-CBD achieved promising results for diabetes control and weight loss in animals during the pre-clinical animal study DIAB-A22-1
The weight loss drug market was valued at $1.90 billion in 2021 and is expected to reach $13.26 billion by 2029, growing at a CAGR of 24.7%
Many drugs used to control diabetes have produced results in managing obesity, which Lexaria plans to leverage with its DehydraTECH(TM) technology

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, recently announced its intent to conduct a human clinical study to examine its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for diabetes control and weight loss. The company has already completed a pre-clinical diabetes study in animals, which supports its advancement to human trials for diabetes control and weight loss (https://cnw.fm/H1XXZ).

Lexaria had announced in two prior press releases, on March 2 and June 16, that its pre-clinical diabetes study DIAB-A22-1 in obese diabetic-conditioned animals, that DehydraTECH-CBD had achieved the…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Publishes Eighth Peer-Reviewed Article in International Journal of Molecular Science

July 24, 2023

July 24, 2023 08:05:00

The article covers the concentration of cannabidiol in hypertensive women and men using the company’s patented DehydraTECH(TM)-processed CBD
The global cardiovascular drugs market is expected to grow from $146.51 billion in 2021, reaching $173.48 billion in 2026, growing at a CAGR of 3.1%
The article supports Lexaria’s efforts as it pursues IND status from the FDA for DehydraTECH-CBD as a potential treatment for hypertension
Company is planning to begin preparations for a clinical trial that could start as early as the fourth quarter

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that its groundbreaking research utilizing its patented DehydraTECH(TM)-processed cannabidiol (DehydraTECH-CBD) has been published in eight peer-reviewed articles across six different publications. Lexaria’s research into DehydraTECH-CBD is being considered for indications including hypertension, diabetes, epilepsy, and more. Hypertension, heart disease, and diabetes are broad fields of interest for the company, with DehydraTECH-CBD generating positive pilot-study data.

“We’re proud of the impressive amount of research that our Company has been able to develop through its HYPER-H21 series of clinical studies that has now been assessed by a variety of our respected peers,” said John Docherty, President of Lexaria (https://cnw.fm/U97ZK). “Lexaria is establishing itself as one of…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) – A Zacks Update

July 11, 2023

July 11, 2023 08:05:00

Lexaria just released its mid-year update, highlighting its key milestones so far and its objectives going forward, summarized in a recent Zacks update
Of note was the company’s most ambitious clinical study yet, HYPER-H21-4, along with its growing patent portfolio that now sees six additional patents awarded across Australia, Japan, the U.S., and Canada so far in 2023
The company also noted its $2 million capital raise back in May, a strong indicator of shareholders’ confidence in the brand, and its efforts to grow its operations
Lexaria looks to build on the momentum gathered so far, and its management is optimistic that it will achieve its objectives for the 2023 calendar year

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released its mid-year update, marking significant strides both in its research and in creating value for its shareholders. In a report by Zacks Small Cap Research, the company’s critical milestones for the current calendar year were highlighted, from recent publications to awarded patents and capital raised thus far.

Of note was Lexaria’s most ambitious clinical study yet, HYPER-H21-4, a clinical study exploring the potential of the company’s patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of hypertension. Enrollments for the study kicked off in April 2022, with dosing beginning ahead of…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

The 2023 Alternative Products Expo, Dallas Chapter – “Everything Counterculture Under One Roof”

July 5, 2023

July 5, 2023 08:05:00

ZJ Events is proud to announce the third leg of its four-part Alternative Products Expo – the Dallas Chapter – that will be held at the Kay Bailey Hutchison Convention Center Dallas. The expo, which promises to be the ultimate event for anyone in the counterculture industry, will serve as a melting pot for everything counterculture, with featured products including CBD, mushrooms, nicotine replacement, dietary supplements, and nootropics, among others.

The event will be held from July 13-15, bringing together hundreds of leading brands such as 3Chi, Mellow Fellow, and Cali Kulture. The event will also offer a platform where attendees can connect with top manufacturers, explore the latest trends and innovations, and even take advantage of exclusive show…

To learn more, please visit https://cnw.fm/M9XqB.

For ticketing info, please visit https://cnw.fm/iecII.

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Robust Intellectual Property Portfolio to 34 Worldwide Patents with Receipt of 4 New Granted in Canada, US

June 28, 2023

June 28, 2023 09:35:00

Lexaria Bioscience recently received four new patents granted in Canada and the United States
In the U.S., the company received two new hypertension-related patents expected to be of particular importance as the company pursues FDA approval for a Phase 1b study evaluating DehydraTECH(TM)-processed CBD
So far, the company has a robust intellectual property portfolio comprising 34 patents granted worldwide
The strong portfolio gives the company the necessary impetus and peace of mind to pursue multiple large markets, starting with the multi-billion dollar cardiovascular drugs market
The company has conducted five human clinical studies that have provided insights into the potential of DehydraTECH-CBD to reduce blood pressure

Lexaria Bioscience’s (NASDAQ: LEXX) intellectual property (“IP”) rests on a strong foundation of granted patents worldwide, a foundation that was recently strengthened by new patents granted in North America. The company, which is developing its patented DehydraTECH(TM) technology platform with the intention of availing it to the masses as an additional step in the manufacturing or processing of active pharmaceutical ingredients (“APIs”) with better bioavailability and bioabsorption properties, celebrated the receipt of four new patents granted in Canada and the United States (https://cnw.fm/ZYNTt).

In Canada, the company has been granted two new patents, the first for Patent Family #1: Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof. According to the company, this is the first patent for this Patent Family issued in Canada, but the 18th patent in this…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) May Announcements Show Resolve to Continue Supporting R&D ‘Lifeblood’

June 15, 2023

June 15, 2023 08:05:00

In May, Lexaria made a number of positive announcements related to its R&D initiatives
In addition to holding its 2023 Annual Meeting, the company completed dosing for its human clinical nicotine study, NIC-H22-1
Lexaria also reported 900% improvements in delivery of DehydraTECH(TM) processed estrogen into blood plasma in an animal study
In a human hypertension study, the company announced that its DehydraTECH-CBD formulation resulted in significant reductions in the blood plasma levels of pro-inflammatory biomarkers (IL 8, 10, and 18)
These biomarkers are linked to cardiovascular disease (“CVD”) and many other conditions, such as asthma, lung diseases, chronic kidney disease, fatty liver disease, Type 1 and 2 diabetes, obesity, and rheumatoid arthritis

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, held its 2023 Annual Meeting on the 9th of May, with shareholders voting on several agenda items, including the election of directors, appointment of auditors, approval of the stock option pricing, approval of the amendment to the maxim number of shares issuable pursuant to the Incentive Equity Plan, and approval of the addition of an evergreen formula to the Incentive Equity Plan. All items put to the vote were approved by the majority, setting the stage for what would become a month of even more positives, particularly around the company’s research and development (“R&D”) initiatives.

“If you’ve been following Lexaria for any period of time, you know that applied R&D is our lifeblood. It helps us establish areas of investigation for commercial pursuits, reduces risks of the unknown for both commercial and regulatory goals, and more,” wrote Lexaria CEO Chris Bunka in the…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields Most Convincing Evidence for Anti-Inflammatory Actions of CBD with its DehydraTECH(TM)-CBD

June 9, 2023

June 9, 2023 08:50:00

Lexaria just announced additional findings from its HYPER-H21-4 human clinical study, highlighting significant reductions in several pro-inflammatory biomarkers associated with cardiovascular disease
This has been termed as “the most convincing evidence in humans,” ultimately showcasing the potential of the company’s patented DehydraTECH(TM)-processed CBD
Other third-party research studies have failed to demonstrate a sustained decrease in resting blood pressure with oral CBD dosing. More so, none have yielded evidence of the anti-inflammatory actions of CBD until Lexaria’s HYPER-H21-4 human clinical study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced additional findings from its HYPER-H21-4 human clinical study that sought to explore the potential of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) in reducing blood pressure (“BP”). Of note was the demonstration of significant reductions in several pro-inflammatory biomarkers associated with cardiovascular disease (“CVD”) in what was described as “the most convincing evidence in humans” of the anti-inflammatory actions of CBD.

“There is some pre-clinical evidence for the anti-inflammatory actions of CBD, but this is likely the most convincing evidence in humans that I have ever seen,” noted Dr. Philip Ainslie, Cardiovascular Advisor to…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Finalizes DehydraTECH(TM)-CBD Batch Manufacturing for IND Filing This Summer and FDA Phase 1b Trial Commencement in October 2023

May 31, 2023

May 31, 2023 08:05:00

Lexaria just announced the completion of batch manufacturing of its patented DehydraTECH(TM)-processed CBD and placebo materials for its FDA Phase 1b HYPER-H23-1 human clinical study
This is in line with the company’s IND filing with the FDA, which it looks to complete this summer, with potential authorization within 60 days
FDA authorization will mark the commencement of Phase 1b trial patient dosing, with the study evaluating the safety and tolerability of DehydraTECH-CBD in hypertensive patients
Filling into capsules of the manufactured DehydraTECH-CBD is expected to be completed before the end of this month, after which analytical release and stability testing will be conducted

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, announced an ambitious plan to embark on its Food and Drug Administration (“FDA”)-registered, U.S. Phase 1b Investigational New Drug (“IND”) hypertension study, HYER-H23-1. Earlier in May, the company announced the awarding of the contract for clinical research organization (“CRO”) services to California-based InClin, Inc. Since this announcement, it has completed batch manufacturing of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) and placebo materials for the study (https://cnw.fm/MR9kR).

Lexaria retained the services of a U.S. contract manufacturing organization to produce these study materials, in line with current Good Manufacturing Practice (“cGMP”) regulations as directed by the FDA. With everything on track, the company looks to file the IND this summer, with potential authorization by…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

The Green Label Expo: Las Vegas 2023 Edition

May 26, 2023

May 26, 2023 09:35:00

The Green Label Expo 2023 edition will be held at the World Market Center in Las Vegas on the 13th & 14th of September, welcoming thousands of CBD experts, alternative product professionals, counterculture experts, and business owners to discover a vast array of global suppliers in trending sectors such as beauty, health & wellness, pet products, foods, business services, and more. As the need for embracing alternative products surges, the vibrant city of Las Vegas is set to welcome the largest trade show for CBD and alternative product professionals. This two-day event will feature an extensive showcase of innovative products/services, industry leaders, and live entertainment bringing the industry closer together while catering to the growing demand for alternative options.

The Green Label Expo will feature thought-provoking seminars and interactive networking sessions throughout the show floor. An impressive lineup of keynote speakers will share the industry trends, latest innovations, and best practices to excel in the fast-growing emerging industries including…

To learn more, please visit https://cnw.fm/6GNLE.

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes $2 Million Public Offering Consisting of Common Shares and Accompanying Warrants

May 23, 2023

May 23, 2023 10:05:00

Lexaria recently completed its 2,106,000-unit public offering at $0.95 per share – representing proceeds totaling over $2 million gross in support of the company’s growth
Maxim Group LLC is acting as the sole placement agent in connection with Lexaria’s offering
Earlier the company was granted four new patents, bringing its total to 32 granted and many more pending worldwide for its patented DehydraTECH(TM) technology
Lexaria is currently seeking IND status from the FDA for use of DehydraTECH-processed CBD with hypertension and expects to begin dosing a new human clinical trial in October 2023

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the closing of its 2,106,000-unit public offering. Each unit consists of one share of common stock, and one warrant to purchase one share of common stock. The common shares and accompanying warrants can only be purchased together in this offering but will be issued by the company separately and will be separable upon issuance.

Each unit in Lexaria’s public offering is being sold at $0.95 and will be immediately exercisable at $0.95 per share and expire five years from the date of issuance. Maxim Group LLC is acting as the sole placement agent in connection with Lexaria’s offering. Before deducting the placement agent fees and…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pivotal Milestones Concerning DehydraTECH(TM) Technology, Including IND Application Plans

May 19, 2023

May 19, 2023 08:05:00

Lexaria’s patented DehydraTECH(TM) technology enhances drug bioavailability, making it useful for a wide range of product formats, including pharmaceuticals, neutraceuticals, consumer packaged goods, and over-the-counter pills, capsules, tablets, and oral suspensions
The company is currently exploring the potential benefits of DehydraTECH related to several molecules including, purified nicotine, CBD, antiviral drugs, human hormones, and PDE5 inhibitors
Lexaria recently announced the completion of its diabetes animal study DIAB-A22-1 with at least three positive outcomes using DehydraTECH-CBD
California-based InClin, Inc. has been awarded the contract for clinical research organization services for the expected upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1
Four new patents have been added to Lexaria’s portfolio, bringing the total to 32 granted patents and more pending worldwide

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is improving how active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules through its patented DehydraTECH(TM) technology. DehydraTECH can be used with a wide range of product formats, including pharmaceuticals, neutraceuticals, consumer packaged goods, and over-the-counter pills, capsules, tablets, and oral suspensions.

Lexaria is focusing its ongoing research and development efforts on advancing product candidates across several key segments, including nicotine replacement, cannabidiol (“CBD”) for…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off FDA IND Filing Process with Granted CRO Contract to California-Based InClin, Inc.

May 16, 2023

May 16, 2023 08:05:00

Lexaria just awarded InClin, Inc. the contract for CRO services, in a move that lines up with the company’s upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1
InClin will manage the study in the form of clinical site evaluation and selection, project management, personnel, site training, and more
Patient dosing is set to kick off as soon as possible once the expected FDA IND filing and review is completed, which Lexaria hopes will be done this summer
HYPER-H23-1 will be Lexaria’s most ambitious study yet, and upon its completion, it will move the company closer to FDA approval of its patented DehydraTECH(TM)-processed CBD

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the awarding of the contract for clinical research organization (“CRO”) services to California-based InClin, Inc. This move is in line with the company’s upcoming Food and Drug Administration (“FDA”)-registered, U.S. Phase 1b Investigational New Drug (“IND”) hypertension study, HYPER-H23-1 that will explore the potential of its patented DehydraTECH(TM)-processed cannabidiol (“DehydraTECH-CBD”) for the treatment of hypertension (https://cnw.fm/8WGqS).

The study will build on five previous Lexaria studies dating back to 2018, which were each successful, evidencing significant reductions in resting blood pressure over acute and multi-week dosing regimens on 134 healthy and hypertensive persons. The studies also showed that DehydraTECH-CBD produced…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Four New Patents Added to the Company’s Growing Patent Portfolio

May 8, 2023

May 8, 2023 08:05:00

Lexaria has received notifications of four new patents either awarded or allowed
After the awarding of these patents, Lexaria’s total patent portfolio will have grown to 32 granted patents worldwide
The new granted patent in Japan is under Patent Family #3: Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents
The new granted Australian patent is under Patent Family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents
The new allowed Canadian patent is under Patent Family #8: Compositions Infused with Nicotine Compounds and Methods of Use Thereof
The new allowed US patent is under Patent Family #21: Compositions and Methods for Treating Hypertension and is the first patent in the Patent Family

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms and the global leader in enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs through its patented DehydraTECH(TM) technology – has announced that the company has received notification of four newly awarded or allowed patents (https://cnw.fm/EDyAd). The new patents will add to Lexaria’s growing portfolio, bringing the total number of patents granted worldwide to 32, with several more pending.

Lexaria’s newly awarded or allowed patents include the following…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX), Featured in Recent Research Report by Zacks SCR

May 3, 2023

May 3, 2023 08:05:00

Zacks recently released a research report covering Lexaria Bioscience, a global innovator in drug delivery platforms
The report discusses the company’s ongoing research and development (“R&D”) programs, forecasting penetration into global markets for hypertension, oral nicotine delivery, and antiviral product categories
Lexaria is targeting conditions with significant market potential, including hypertension, diabetes, dementia, and seizures
These programs position the company for entry into collaborative opportunities to support further growth and provide growth capital

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, featured in a recently released research report from Zacks Small-Cap Research (“SCR”) (https://cnw.fm/R891E). The report considers the potential approval and commercialization of products processed with the company’s patented DehydraTECH(TM) drug delivery platform technology that increases drug bioavailability, and ongoing research and development (“R&D”) activities, including recent revelations that the platform technology may offer a new mechanism of action, to support a $14.00 share valuation (https://cnw.fm/e2bXG).

“DehydraTECH offers several attractive features: substantial improvement in bioabsorption in terms of time to measurable plasma levels and AUC (area under the curve), brain permeation, taste masking, and side effect reduction. As DehydraTECH does not employ a covalent bond, [it] is not a new molecular…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Successful DIAB-A22-1 Diabetes Study Indicates Just One of Several Potential Applications for DehydraTECH(TM) Drug Delivery Platform Technology

April 28, 2023

April 28, 2023 08:50:00

Lexaria recently completed its diabetes animal model study, DIAB-A22-1, an ambitious study that explored the potential of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of diabetes
The study showed at least three primary positive outcomes, including weight loss and improved triglyceride and cholesterol levels, with lower doses of DehydraTECH-CBD achieving the most optimum outcome
The success of this study inches Lexaria closer to capitalizing on the potential of the diabetes drug market, estimated at $63.1 billion in 2021
It also points to the technology’s effectiveness, particularly following the success of the company’s most ambitious clinical study, HYPER-H21-4, demonstrating the potential of DehydraTECH-CBD for the treatment of hypertension

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms. The company’s patented DehydraTECH(TM) drug delivery platform technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of active pharmaceutical ingredients. They recently completed its diabetes animal model study DIAB-A22-1, an ambitious study that explored the potential of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of diabetes. The study produced at least three positive outcomes in what Lexaria’s management described as “encouraging,” further indicating many prospective benefits worthy of further investigation together down the line (https://cnw.fm/fw4H8).

The study, which involved 32 male Zucker (“ZDF”) rats- 24 obese and eight lean, saw the administration of Lexaria’s “DehydraTECH-CBD 2.0” formulations at either 30 mg/Kg or 100 mg/Kg of body weight. Following initial positive early responses witnessed, the study, which was to last for four weeks, was…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes the Licensed Use of its DehydraTECH(TM) Technology to Complement its Royalty Earnings and Realize Revenue in Advance of Royalties

April 17, 2023

April 17, 2023 08:50:00

Chris Bunka, Lexaria’s CEO, has reiterated the company’s commitment to creating value for its shareholders with the licensed use of its patented DehydraTECH(TM) technology
Mr. Bunka has noted that Lexaria is already in discussions with interested parties in Europe and North America, a move that presents a critical fiscal opportunity for the company
He has emphasized how profitable new licensing agreements could be for the company, presenting additional avenues for Lexaria to generate revenue and create value for its shareholders
As the company continues to make a transition toward a more commercial focus in 2023, Bunka notes that licensing will play an integral part

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has, since its inception, stayed committed to creating shareholder value and exploring different avenues for growth. This outlook has informed the company’s ambitious clinical studies, starting with the HYPER-H21-4 clinical study demonstrating a novel mechanism of action of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) capsule formulation for the reduction of blood pressure. It has also shaped other studies, including, but not limited to, diabetes, nicotine replacement, antivirals, and human epilepsy.

In the most recent annual letter to all stakeholders, dated January 2023, Chris Bunka, Lexaria’s CEO, reiterated the company’s commitment to creating value for its shareholders. Of note was his mention of the licensed use of its DehydraTECH technology, both for consumer sectors and the pharmaceutical…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Revolutionizing Drug Delivery Potential for Active Pharmaceutical Ingredients Using Patented DehydraTECH(TM) Technology

April 10, 2023

April 10, 2023 08:05:00

DehydraTECH(TM)-enabled drugs and product formats improve the speed of onset, increase bioavailability, increase brain absorption, enhance drug potency, reduce drug administration costs, and mask unwanted tastes, shown effective with a growing number of medical applications
Current DehydraTECH studies (animal and human) include hypertension, dementia, oral nicotine, epilepsy, and diabetes
Most recently, Lexaria’s DehydraTECH-CBD studies for hypertension have produced positive results, and the company is seeking IND status with the FDA

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed a disruptive drug delivery technology with multiple opportunities for success in cannabinoids, oral nicotine and other active pharmaceutical ingredients (“APIs”). Lexaria’s patented DehydraTECH(TM) technology is a formulation and dehydration processing procedure that changes how the body detects and absorbs drugs. The company currently has 28 granted patents, with many more pending patents in countries worldwide.

Lexaria specifically designed DehydraTECH for formulating and delivering topical or oral lipophilic (fat-soluble) drugs and APIs to increase effectiveness and improve how they enter the…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Multiple Commercial Applications for Its Patented DehydraTECH(TM) Technology Platform

April 5, 2023

April 5, 2023 08:05:00

Lexaria Bioscience, a global innovator in drug delivery platforms, has developed and patented the DehydraTECH(TM) drug delivery platform technology
The company has undertaken multiple studies as part of its extensive R&D program involving DehydraTECH, which continues to yield positive results
This R&D program is focused on the development of product candidates across four main segments, which represent the platform’s potential commercial applications
These segments include the development of DehydraTECH-processed cannabidiol (“CBD”) for hypertension, epilepsy, diabetes and dementia; DehydraTECH-processed oral nicotine; other pharmaceutical areas exploring a wide range of DehydraTECH-processed active molecules; and hemp-derived CBD applications for consumer packaged goods (“CPG”)
Currently, Lexaria is prioritizing research on DehydraTECH-CBD as a potential treatment for hypertension

Recent advancements in drug delivery techniques have improved, among others, the efficiency and safety of therapeutic treatments and active pharmaceutical ingredients (“APIs”). In fact, analyzing these improvements through the findings obtained by Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, demonstrates the progress is remarkable. Headquartered in Kelowna, British Columbia, the company developed and patented the DehydraTECH(TM) drug delivery platform technology, which is essentially an additional step easily incorporated into the formulation and manufacturing process of existing or new orally ingestible and topical lipophilic (fat-soluble) products.

“This step involves mixing the active ingredient as a delivery ‘payload’ together with certain fatty acids, infusing the mixture into a substrate material, and then using controlled dehydration synthesis processing to associate the payload and fatty acids together at a molecular level, before integrating the…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) CEO, Chris Bunka, Confident that 2023 will be Lexaria’s Best Year Ever

April 3, 2023

April 3, 2023 08:05:00

Chris Bunka, Lexaria’s CEO, remains confident that 2023 will be Lexaria’s best year ever and has expressed his optimism that the company will continue to build its client base and increase its cash flows as the year progresses
In his 2023 letter to stakeholders, the CEO expressed his satisfaction given that the company had delivered on a statement that he made the previous year, lauding his team for meeting objectives that Lexaria had set out to achieve in the 2022 calendar year
Through the help of his team, Bunka is committed to making Lexaria one of the top drug delivery performers in the biotech/pharmaceutical world, starting with the launch of its FDA-registered IND program to investigate its patented DehydraTECH(TM)-processed CBD for the potential treatment of hypertension

Back at the start of the 2022 calendar year, Chris Bunka, the CEO of Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, released his annual letter to all stakeholders. Of note was his emphasis on the company’s initiatives to have multiple choices in how it was funded, specifically trying to position Lexaria for non-dilutive injections of capital through strategic partners and other commercial relationships (https://cnw.fm/icp9D).

In his 2023 letter, Bunka expressed his satisfaction and pleasure, given that the company delivered on the statement he made the previous year, pointing to his team for delivering objectives that Lexaria had…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Drug Delivery Technology Demonstrates Growing List of Potential Applications as Evidenced Through Numerous R&D Programs

March 24, 2023

March 24, 2023 08:50:00

DehydraTECH(TM) is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, topicals, oral suspensions and more
The patented technology increases the speed of onset, bioavailability, brain absorption, and reduces drug administration costs
Lexaria currently has multiple R&D programs – yielding successful results and further opportunities for additional study models

Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, is increasing bioavailability and improving the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery with its patented DehydraTECH(TM) technology. DehydraTECH is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, topicals, oral suspensions and more.

Most recently, a company announcement indicates that a just-completed DIAB-A22-1 diabetes study has produced at least three positive outcomes, including weight loss in obese diabetic-conditioned animals and shown improved triglyceride and cholesterol levels (https://cnw.fm/ORSPL). The animals tested in…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Tracking Proprietary Path to Drug Delivery Innovation and Commercialization on Robust R&D Programs

March 21, 2023

March 21, 2023 08:50:00

Lexaria Bioscience is a global innovator in drug delivery platforms
The company has been developing and commercializing patented DehydraTECH(TM), a technology that has been shown to increase the bioavailability of fat-soluble active molecules, improve the speed of onset and provide other benefits across multiple applications
Lexaria has undertaken numerous R&D programs in an effort to build relationships with prospective corporate partners to out-license the technology or to form other profitable corporate relationships
The company owes its achievements to its focus on R&D and the guidance provided by its highly experienced leadership, including CEO Chris Bunka, President John Docherty, as well as a dedicated and active board of directors

Lexaria Bioscience’s (NASDAQ: LEXX) path to becoming a global leader and innovator in drug delivery traces its origins to 2014, when CEO Chris Bunka redirected the company to its current business, focusing on the research and development (“R&D”) of the delivery of lipophilic active molecules based on its patented DehydraTECH(TM) technology. Protected by 28 granted patents worldwide, with many more pending around the world, the technology can lay claim to the potential of disrupting the drug delivery space as it is known today.

Typically, a drug delivery system is a formulation or a device that enables the introduction of a therapeutic substance into the body. It is specifically designed to improve the substance’s efficacy and safety by controlling the rate, time, and place of release of drugs in the…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Encouraged by Positive Findings from its DIAB-A22-1 Animal Model Study on Potential DehydraTECH-CBD(TM) Treatment for Diabetes

March 14, 2023

March 14, 2023 08:05:00

Lexaria’s DIAB-A22-1 animal model study just concluded, highlighting three positive outcomes, including an improvement in general activity, significant reductions in body weight, and improved triglyceride and cholesterol levels
The study was undertaken by a third-party testing laboratory in Canada involving 24 obese and eight lean rats for a total of 32 male Zucker rats
The success of this DIAB-A22-1 study marks a significant milestone for Lexaria, even as it continues to explore its patented DehydraTECH(TM) technology application in various other areas, including nicotine replacement, epilepsy, hypertension, dementia and more
With its unique product offering, a growing list of patents, and unique market positioning, Lexaria is becoming a key player in the drug delivery technology space

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the completion of its DIAB-A22-1 animal model study, which explored the potential of the patented DehydraTECH(TM)-processed CBD to treat diabetes. Of note were three positive outcomes, including an improvement in general activity, reductions in body weight, and better triglyceride and cholesterol levels.

The study, undertaken by a leading, third-party testing laboratory in Canada, administered select Lexaria “DehydraTECH-CBD 2.0” formulations with doses of either 30 mg/Kg or 100 mg/Kg of body weight. It involved 24 obese and eight lean rats for a total of 32 male Zucker (“ZDF”) rats. As Lexaria’s first study in…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

India Globalization Capital Inc. (NYSE American: IGC) Focused on Fighting Alzheimer’s Disease with First-of-Kind Treatments in Study Phase

March 7, 2023

March 7, 2023 09:35:00

Government showing strong support for bills aimed at treating Alzheimer’s disease
IGC’s leading drug candidate recently completed phase 1 of a safety and tolerability trial, and entered phase 2
Company’s proprietary treatments have “the potential to revolutionize the treatment of Alzheimer’s disease”

Key legislation designed to fight Alzheimer’s has been introduced in Congress — or actually reintroduced: the NAPA Reauthorization Act was first introduced in the last Congress but is seeing continued support from the current group of elected officials (https://cnw.fm/xqOnK). Support for the treatment of Alzheimer’s is essential for organizations such as India Globalization Capital (NYSE American: IGC), a company pursuing effective treatment for Alzheimer patients suffering with agitation and other neuropsychiatric symptoms.

“The Alzheimer’s Association and the Alzheimer’s Impact Movement (“AIM”) are proud to support the bipartisan introduction of the NAPA Reauthorization Act and the Alzheimer’s Accountability and Investment Act,” reported a recent Alzheimer’s…

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://cnw.fm/IGC

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX), a Global Innovator in Drug Delivery Platforms, Holds Discussions With Several Larger Companies on Path to Commercialization of DehydraTECH(TM) Technology

March 7, 2023

March 7, 2023 08:05:00

Lexaria’s patented DehydraTECH(TM) technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of active pharmaceutical ingredients
The company out-licenses the use of its patented DehydraTECH(TM) technology within the pharmaceutical industry and consumer sectors
Lexaria has focused on applied R&D to establish areas of investigation for commercial pursuits, with its programs proving successful
Additionally, Lexaria has a robust intellectual property portfolio with 28 patents granted worldwide as of February 2023

In 2022, Lexaria Bioscience (NASDAQ: LEXX), a global innovator developing and commercializing its patented DehydraTECH(TM) drug delivery technology, achieved several important goals for the year, according to CEO Chris Bunka.

“One of our biggest achievements of 2022 was our greater emphasis on commercial pursuits,” Bunka wrote in his January 2023 letter to shareholders (https://cnw.fm/gm32a). This saw the company acquire new customers, among them Premier Wellness Science Co. Ltd. of Japan, its first client in…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Additional HYPER-H21-4 Study Findings Offer Better Understanding of the Anti-Hypertensive Effects of DehydraTECH-CBD

February 27, 2023

February 27, 2023 10:35:00

Dosing for Lexaria’s ambitious and most comprehensive clinical study, HYPER-H21-4, was successfully completed in July 2022, with newly analyzed results now emerging
Its latest findings bring the company closer to its upcoming FDA Phase 1b study while also explaining the patented DehydraTECH-(TM)-processed CBD interaction with the sympatho-chromaffin system via catestatin modulation
Lexaria’s management is optimistic that DehyraTECH-CBD and its effectiveness in modulating catestatin levels could become a significant value enhancer should it eventually enter the marketplace as an approved hypertension treatment

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, kicked off its human clinical study, HYPER-H21-1 in 2021, focused on testing its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for the potential use as a hypertension treatment alternative (https://cnw.fm/4sQYN). On July 27, 2022, the company announced that the dosing for its HYPER-H21-4 multi-week human clinical study was successfully completed, with no serious adverse events resulting from the dosing (https://cnw.fm/imOSQ).

This safety-related outcome – no serious adverse events – is generally speaking the desired…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Alternative Products Expo Announces Its Upcoming Fort Lauderdale 2023 Show

February 22, 2023

February 22, 2023 10:20:00

Alternative Products Expo has just announced its next show, which will take place on March 3-5, 2023, in the beautiful city of Fort Lauderdale, Florida. This one-of-a-kind trade show promises to provide attendees with a unique experience that breaks away from the monotony of traditional events. It’s a must-attend for anyone in the smoke shop and counterculture industry.

Known for short as Alt Pro Expo, this event has its roots in the Vape and CBD world and has since expanded to include a plethora of industries. With over 200 exhibitors representing various product categories, such as…

For more information, please visit https://altproexpo.com/

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expecting Additional Growth in 2023, Including IND Filing and IND Clinical Study

February 10, 2023

February 10, 2023 08:05:00

In addition to a recently released shareholder update letter from the company’s CEO, Chris Bunka, Lexaria Bioscience has now released a new investor presentation
Despite 2022 inflationary conditions, Lexaria has seen growth company-wide – including hitting annual budgets +/- 2% over the last two years
Lexaria’s patented DehydraTECH(TM) technology offers more effective delivery of active pharmaceutical ingredients into the bloodstream and brain tissue with 28 patents granted and roughly 50 patent applications pending worldwide
For Q1 2023, Lexaria expects additional results from its hypertension study HYPER-H21-4, dosing completion in its animal dementia study and diabetes study, dosing completion in human nicotine study NIC-H21-1, and submissions and publishing of additional results in research journals
Lexaria’s anticipated mid-year IND filing would be an important milestone for the company, providing additional interaction with the pharmaceutical industry

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has released its new corporate presentation (https://ir.lexariabioscience.com/presentations). The presentation augments the positive outlook for the coming year put forth in an earlier released shareholder update letter from the company’s CEO, Chris Bunka.

Bunka starts the letter with, “As 2022 came to a close, it isn’t news that nearly all companies – not to mention most people – are facing challenges not experienced in years. Lexaria continues to navigate well and is focused on those things it can control, such as applied R&D designed to entice others to…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) – Technology Behind Patented Disruptive DehydraTECH(TM) Drug Delivery Platform

February 8, 2023

February 8, 2023 08:05:00

Lexaria has developed the DehydraTECH drug delivery technology, which enhances the performance of multiple categories of fat-soluble active molecules and drugs
DehydraTECH has been shown to increase intestinal bioabsorption of certain bioactive compounds by as much as 27 times, with its onset of action being as little as 1.5 minutes
The technology is also expected to lower the overall drug costs because it delivers more active molecules to the blood plasma and brain, thus necessitating lower dosing, all while resulting in cost-effective manufacturing
DehydraTECH is protected by 28 patents granted worldwide, with approximately 50 more pending

Speaking during a late 2022 interview (https://cnw.fm/w4qAD), Chris Bunka, the Chairman and CEO of Lexaria Bioscience (NASDAQ: LEXX), emphasized the varied applications of DehydraTECH(TM), and that, for example, the company intends to help people quit smoking by enabling them to satisfy their nicotine cravings in a way that will not kill them: pouches. This comes against a backdrop of worrying statistics, which show that over 480,000 people in the United States (https://cnw.fm/x4FoR) and over 8 million people globally (https://cnw.fm/64clk) die annually from cigarette smoking.

Lexaria also sees an opportunity to help people with hypertension, which affects about 116 million people in the US (https://cnw.fm/lU3oV) and seizure disorders, which affect 3.4 million people in the US and 65 million globally (https://cnw.fm/tn9sT). “We really do believe Lexaria is going to make the world a better…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) To Intensify Focus on Commercial Execution of its DehydraTECH Technology for the 2023 Calendar year

February 6, 2023

February 6, 2023 08:05:00

2022 saw Lexaria introduce its patented DehydraTECH(TM) technology to world-leading collaborators while also exploring DehydraTECH-CBD for the potential treatment of hypertension
It also saw success in its research for the potential treatment of conditions such as epilepsy, making the year Lexaria’s most active one yet
Significant progress was made on key objectives in 2022, a feat which the company plans to capitalize on and leverage to scale up the commercial execution of its technology in 2023
To facilitate this, Lexaria has brought on board Julian Gangolli, former President of GW Pharmaceuticals USA, as a strategic advisor. Chris Bunka, Lexaria’s CEO, anticipates 2023 to be the “best year ever”

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has set its focus on the commercial execution of its robust patented DehydraTECH(TM) technology portfolio for the 2023 calendar year. The company plans to capitalize on the success of 2022, which saw the fulfillment of primary objectives.

In 2022, Lexaria introduced DehydraTECH to world-leading collaborators and explored DehydraTECH-processed CBD for the potential treatment of hypertension. The company also saw success in its research for the potential treatment of conditions such as epilepsy making the year Lexaria’s most successful…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Anticipating ‘Best Year Ever’ in 2023

January 27, 2023

January 27, 2023 08:05:00

Lexaria Bioscience recently released its 2023 annual letter from CEO Chris Bunka, providing a strategic update to all stakeholders
The letter highlights the key milestones achieved in calendar 2022, outlines expectations for calendar 2023, and indicates why Chris Bunka expects 2023 to be the company’s best year so far
1In calendar 2023, Lexaria expects to attain FDA registration for an investigational new drug (“IND”) program and commence Phase 1(b) clinical study evaluating the safety and tolerability of DehydraTECH(TM)-processed CBD as a treatment for hypertension
The company will also be pursuing commercial relationships in 2023 even as its R&D continues to progress by engaging in discussions with potential collaborators who may license the patented DehydraTECH technology

Lexaria Bioscience (NASDAQ: LEXX) started calendar 2022 with optimism, which according to CEO Chris Bunka’s recently published annual letter to shareholders (https://cnw.fm/doJop), turned out to well founded. Now, as the company begins calendar 2023, “that optimism is, if anything, even stronger today.” Lexaria has reason to be optimistic about the current year, coming off a year that saw it successfully fulfill its primary objectives and tick most, if not all, of the boxes on its priority list.

At the start of calendar 2022, the company intended to introduce its patented DehydraTECH(TM) drug delivery technology to world-leading collaborators and to avoid raising additional funds through the capital markets. It also planned to develop its DehydraTECH-CBD hypertension program, explore…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability to Meet Underserved Medical Needs

January 25, 2023

January 25, 2023 08:50:00

Bioavailability measures the amount of a substance that enters the bloodstream, with most oral routes providing lower amounts of the drug due to poor bioavailability
Studies on nutrients show that not all the nutrients we ingest actually enter the bloodstream due to inhibiting factors in the digestive tract
Lexaria’s patented DehydraTECH(TM) technology helps increase bioavailability for active pharmaceutical ingredients (“APIs”), which has been shown through various animal and human clinical studies

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using its patented DehydraTECH(TM) technology to improve bioavailability and how active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with the speed of onset, and brain absorption. Lexaria is focusing ongoing research and development efforts on the advancement of product candidates across several key segments, including, nicotine replacement, CBD, cardiovascular drugs, antivirals, epilepsy, human hormones, and PDE5 inhibitors.

Bioavailability measures how much of a substance enters the bloodstream, with intravenous administration being the most effective approach to 100% bioavailability for maximum effect. While oral administration is less intrusive and preferred, it presents less efficacy and bioavailability of APIs due to…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

India Globalization Capital Inc. (NYSE American: IGC) Announces Beginning of Phase 2 Clinical Trials for Proprietary Drug Candidate in Treating Alzheimer’s

January 17, 2023

January 17, 2023 11:05:00

Believed to be the first natural low-doses of THC-based compound to enter human trials for Alzheimer’s
IGC-AD1 has the potential to revolutionize the treatment of Alzheimer’s disease
The clinical trial is expected to produce data to “help us to further understand the metabolism of IGC-AD1 for a diverse population,” says CEO

In a historic first, India Globalization Capital (NYSE American: IGC) has begun Phase 2 clinical trials evaluating its flagship drug candidate, IGC-AD1, for the treatment of agitation in dementia from Alzheimer’s disease (https://cnw.fm/LGAZG). Company officials noted that, to their knowledge, this is the first natural low-dose THC-based compound to enter human trials for the treatment of symptoms such as agitation in dementia from Alzheimer’s disease. Currently there is no FDA-approved medication to treat agitation in Alzheimer’s.

“We believe IGC-AD1 has the potential to revolutionize the treatment of the symptoms (agitation) of Alzheimer’s disease as the only natural low-dose THC-based formulation candidate currently undergoing FDA testing,” said IGC CEO Ram Mukunda. “Approximately 8 million people are affected by Alzheimer’s…

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://cnw.fm/IGC

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Adds to its Existing Suite of Global Patents with First Granted Patent in Canada

January 11, 2023

January 11, 2023 08:50:00

Lexaria has announced patent #3,093,414, its first patent in Canada, its 28th granted patent worldwide, and the first patent from its sixth patent family
This patent joins the ranks of previously issued patents in Australia, India, Japan, and the EU, even as similar patent applications for skin-based delivery of patented DehydraTECH formulations remain pending in many countries
In Lexaria’s 2018 study, DehydraTECH-processed CBD demonstrated almost a 1,900% increase in CBD permeability through human skin compared to a control formulation that was devoid of any commercial penetration enhancers
This patent inches Lexaria closer to taking advantage of the cosmeceuticals market, projected to hit $95.95 billion by 2030, and the global skincare market that is estimated to post a CAGR of 4.6% over the forecast period (2021-2030)

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced its 28th granted patent worldwide and the first granted patent from its sixth patent family, titled “Transdermal And/Or Dermal Delivery Of Lipophilic Active Agents.” The Canadian patent #3,093,414 is for improved compositions and methods for transdermal and dermal delivery of cannabinoids, including cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”), all established on the company’s patented DehydraTECH technology (https://cnw.fm/cMrMY).

This patent comes three months after Lexaria was granted its 27th worldwide patent in Mexico and just eight months since it was awarded its 25th patent in the United States for “Compositions and Methods For Enhanced Delivery of Antiviral Agents.” It joins the ranks of previously issued patents in…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed CBD Can be Administered More Effectively at Lower Levels than Other CBD, Boosting Hope for Hypertension Patients

January 9, 2023

January 9, 2023 09:35:00

Lexaria, a global innovator in drug delivery platforms, has developed the patented DehydraTECH(TM) platform technology, which has been shown to increase the bio-absorption of various fat-soluble active molecules and drugs
In a recently completed study, Lexaria showed that DehydraTECH-processed CBD had exceptional safety and tolerability profile in addition to resulting in a statistically significant lowering of 24-hour ambulatory blood pressure
The company also reported that it had demonstrated superior CBD blood absorption levels in its HYPER-H21-4 study from DehydraTECH-CBD relative to those of published comparators
At the lowest (3.38 mg/kg) and highest (4.46 mg/kg) dose levels tested, DehydraTECH-CBD resulted in 45.8% and 133.4% higher average blood plasma levels, respectively, than the figure reported when a higher (5 mg/kg) dose level of non-Lexaria, pharmaceutical-grade CBD was administered

Global innovator Lexaria Bioscience (NASDAQ: LEXX) has developed a proprietary platform technology that is capable of delivering certain drug molecules more effectively into the human body than their generic forms. That, CEO Chris Bunka contends (https://cnw.fm/FEXdl), allows for various efficiencies and decreases in adverse side effects.

Known as DehydraTECH(TM), the patented technology can be easily incorporated into the formulation and manufacturing processes of existing or new orally ingestible and topical products, according to the company, provided the products are fat soluble. So far, Lexaria has been able to process…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Acquisition of Franchise Global Health Completed, Rapid Jump in Potential for European Cannabis Sales

January 6, 2023

January 6, 2023 10:20:00

International cannabis operator Flora Growth Corp. is rapidly expanding its global footprint and Colombia-based international supply chain thanks to strategic acquisitions during the past several months
Flora’s most recent acquisition was concluded just before Christmas on finalization of an agreement with multi-national operator Franchise Global Health Inc. that strengthens Flora’s position in Europe
Franchise Global Health (“FGH”) serves 1,200 pharmacies in Germany, which the companies regard as the doorway to the rest of Europe, and it also has a footprint in Portugal and Denmark, while Flora Growth has completed exports to Switzerland and the Czech Republic
Flora reported a 604 percent YOY increase in revenues for the first half of the year and recently added an increase of 414 percent YOY for the Q3 period

Cannabis cultivator and global distributor Flora Growth (NASDAQ: FLGC) is entering the new year with its latest acquisition completed, opening the way for accelerated expansion into Europe’s marketplace.

Franchise Global Health Inc. (TSX.V: FGH) announced Dec. 23 that it had completed arrangements for Flora Growth to acquire its issued and outstanding shares, and that the former holders of common shares of Franchise Global Health would be delisted from the TSX Venture Exchange on or about Dec. 28 as…

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Dosing Begins in Lexaria Bioscience Corp. (NASDAQ: LEXX) Human Clinical Study, Evaluating DehydraTECH(TM)-Nicotine Against Leading Nicotine Oral Pouch Brands

January 4, 2023

January 4, 2023 10:20:00

The 36-person human pharmacokinetic randomized, double-blind, cross-over study NIC-H22-1 will compare its patented DehydraTECH(TM)-nicotine to leading nicotine pouches On! and Zyn
The white pouch oral delivery of nicotine is thought to avoid harmful lung outcomes that smokers and vapers experience
The global nicotine pouch market was valued at $2.33 billion in 2020 and is expected to reach $21.84 billion by 2027, driven by an increase in the number of consumers seeking alternative forms of nicotine that do not involve lung exposure

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, announced that dosing has commenced for its human clinical nicotine study NIC-H22-1. The study is a 36-person human pharmacokinetic randomized, double-blind, cross-over study conducted on current cigarette smoking subjects. Each participant will visit the laboratory and be dosed three times over the coming weeks. Only one oral nicotine pouch will be administered and evaluated during each visit. Participants will either receive Lexaria’s patented DehydraTECH(TM)-nicotine, On! brand manufactured by Altria, or Zyn brand manufactured by Swedish Match during that time (https://cnw.fm/QLXXQ).

The objectives of the NIC-H22-1 study are to determine the quantity of nicotine in blood at various time points and vital-sign data collection of temperature, blood pressure, heart rate, and respiratory rate. The company also plans to collect subjective evaluations, including…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability in Pharmaceuticals

December 27, 2022

December 27, 2022 11:05:00

Studies have indicated that around 40% of the available drugs on the market offer poor bioavailability
Lexaria’s patented DehydraTECH(TM) technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery
The global pharmaceutical drug delivery market was valued at $1.66 billion in 2021 and is expected to grow at a CAGR of 5.9%, resulting in a value of $2.21 billion by 2026

One of the main concerns associated with marketed drugs is low bioavailability. Bioavailability is the amount of a drug or substance that becomes completely available to the intended biological destination and is a measure of the rate and fraction of the initial dose of the drug that successfully reaches either the site of action or the bodily fluid domain in which the intended target has unimpeded access. Bioavailability is integral to pharmacokinetics, the study of drug movement through the body. Pharmacokinetics is often represented by the acronym ABCD – administration, bioavailability, clearance, and distribution (https://cnw.fm/29C2S).

Various studies have indicated that around 40% of available drugs are poorly bioavailable (soluble) (https://cnw.fm/mLG2Z). Many factors can affect the bioavailability of drugs and…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Luis Merchan, Helping Flora Growth Corp. (NASDAQ: FLGC) Become Global Leader in the CBD Space

December 22, 2022

December 22, 2022 08:05:00

Luis Merchan was appointed President of Consumer Goods at Flora in July 2020 before being appointed as the company’s CEO five months later, and chairman of its Board of Directors in May 2022
Merchan would lend his years of experience at Macy’s, where he led various sales and marketing initiatives, including the B2B corporate team responsible for bringing in $160 million in annual revenue
Under his leadership, Flora has transitioned from the development stage to a full-scale international distributor with operations in over 12 countries worldwide. Mr. Merchan has also spearheaded several M&As, all of which have since set the company up for rapid growth
Flora maintains its revenue guidance for FY 2022 to be between $35 and $45 million, incorporating revenue contributions from its various operating divisions, including Vessel Brand

In July 2020, Flora Growth (NASDAQ: FLGC), a cannabis cultivator, brand manufacturer, and global distributor, appointed Luis Merchan as the President of Consumer Goods. Mr. Merchan would lead the company’s CBD portfolio, eventually launching four unique brands in the United States and facilitating the growth of the company’s operating divisions (https://cnw.fm/ZeVsJ). His performance would influence his appointment as CEO of the company five months later, taking over from Damian Lopez.

Before joining Flora, Mr. Merchan held various positions at Macy’s Inc., including Vice President (“VP”) of Workforce Strategy and Operations, VP of Customer Experience and Selling Support Services, and…

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing the Seizure Treatment Market with Successful EPIL-A21-1 Animal Study

December 15, 2022

December 15, 2022 08:05:00

Epilepsy affects one in every 26 people globally, with as many as one million ED visits, 280 hospital admissions, average hospital stays of 3.6 days, and an aggregate hospital cost of approximately $2.5 billion annually
With its severity, prevalence, and overall cost implications, Lexaria is looking to offer an alternative option with its patented DehydraTECH(TM)-CBD
Its recent animal seizure study, EPIL-A21-1, showed DehydraTECH-CBD to be equally or even more effective at lower doses than Epidiolex, one of the world’s leading anti-seizure medications and the world’s only commercially approved CBD-powered anti-seizure drug
Lexaria looks to build on the findings so far to establish a better understanding of DehydraTECH-CBD for the potential treatment of seizures, a market projected to be valued at $16.6 billion by 2031

According to the Epilepsy Foundation, epilepsy is the fourth most common neurological condition globally, affecting one in every 26 people. About 48 out of every 100,000 people are diagnosed with the condition every year, and as of 2019, it affected approximately 50 million people (https://cnw.fm/OGF3x). With the condition leading to as many as one million emergency department (“ED”) visits and over 280,000 hospital admissions, it attracts average hospital stays of 3.6 days for the patients, with an aggregate hospital cost totaling approximately $2.5 billion annually (https://cnw.fm/Mlp9d).

Given the severity, prevalence, and overall cost implications associated with this condition, there is a dire need for treatment options that are not only effective but also affordable. Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, seeks to meet that need with…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 2022 Calendar Year in Review

December 13, 2022

December 13, 2022 09:35:00

Lexaria Bioscience is a global innovator in drug delivery platforms whose patented DehydraTECH(TM) technology has demonstrated the ability to improve the bioavailability and increase the speed of onset of many drugs
In calendar 2022, the company achieved a number of milestones in various areas, including research programs, receipt of patents, and licensing agreements
Lexaria started and completed its fourth and most comprehensive hypertension study yet, investigating the capabilities of DehydraTECH-CBD, with the study showing that its formulation resulted in a sustained reduction in blood pressure over the study period (five weeks)
The company has also started investigating DehydraTECH-CBD as a potential therapeutic for the treatment of dementia and diabetes and is planning to begin another study on DehydraTECH-nicotine pouch performance
Over the course of the year, Lexaria was granted four new patents, and entered into separate licensing agreements with four new partners

In his concluding remarks in this year’s letter to shareholders published January, Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka underlined that “Management of [the company] feels we are on track, on schedule, and on budget to deliver what we hope and expect will be great results in 2022” (https://cnw.fm/gfw3L). Since then, the company has achieved crucial milestones that can well be described as “great results,” and rightly so. These milestones are centered around Lexaria’s patented DehydraTECH(TM) drug delivery technology.

DehydraTECH can be applied to many drugs and fat-soluble active pharmaceutical ingredients (“APIs”), with the resultant formulation boasting better speed of onset, bioavailability, and brain absorption. So far, Lexaria has evidenced, through pharmacokinetic (“PK”) studies, that its technology delivers higher…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Findings of Animal Anti-Seizure Study Program Suggesting that DehydraTECH(TM)-CBD Is More Effective at Lower Doses and Works More Rapidly than FDA-Approved Epidiolex

December 7, 2022

December 7, 2022 08:05:00

Lexaria recently announced the findings of the first two studies from its EPIL-A21-1 animal research program
The program is designed to assess the effectiveness of patented DehydraTECH(TM)-CBD in reducing or eliminating seizure activity compared to Epidiolex, a CBD-based anti-seizure drug
The first study evidenced that DehydraTECH-CBD is more efficacious at lower doses than Epidiolex
The second study demonstrated DehydraTECH-CBD’s enhanced effectiveness; specifically, the formulation acted more rapidly than Epidiolex

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) formulation has demonstrated performance enhancements compared to Epidiolex(R), the first and only FDA-approved CBD medication for the treatment of seizures (https://cnw.fm/onsUy).

Initiated in March this year and conducted by a leading US-based independent laboratory, the EPIL-A21-1 animal research program was designed to assess the seizure-inhibiting activity and efficacy of DehydraTECH-CBD at lower doses than were required with Epidiolex. Through the program, Lexaria…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Forward With Exploration of Patented DehydraTECH(TM)-Processed CBD for Dementia

December 2, 2022

December 2, 2022 08:05:00

Approximately 55 million people worldwide have dementia, which is expected to grow to 78 million by 2030
The dementia treatment market was valued at $13.78 billion in 2021. The market is expected to grow at a CAGR of 8.32%, resulting in a value of $26.13 billion by 2029
Clinical studies have established a connection between hypertension and dementia
With DehydraTECH(TM)-CBD already evidencing that it can lower blood pressure and its propensity to cross the blood-brain barrier, Lexaria is investigating the potential for a positive outcome in the DEM-A22-1 study

According to the World Health Organization (“WHO”), dementia is the seventh leading cause of death among all diseases and one major cause of disability and dependency among older people worldwide. Dementia is characterized by the deterioration of cognitive function, affecting memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgment. Although consciousness is not impaired, it is commonly accompanied by mood changes, emotional control deficits, behavior changes, and motivational impairments. It is estimated that approximately 55 million people have dementia worldwide, a number expected to grow to 78 million by 2030 (https://cnw.fm/lYnyd).

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is exploring its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for use against dementia. As previously evidenced in animal studies, DehydraTECH-CBD crosses the blood-brain barrier much more…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Investigation of DehydraTECH-CBD’s Potential Therapeutic Value for Diabetes and Defmentia with New Studies

November 29, 2022

November 29, 2022 08:05:00

Lexaria’s Patented DehydraTECH technology improves the bioavailability of pharmaceuticals and therapeutics for a number of developing applications
Lexaria is set to complete its DEM-A22-1 and DIAB-A22-1 studies on dementia and diabetes, respectively, in January 2023, with analysis and reporting set to follow soon after
These studies will build on the just-concluded hypertension clinical study whose results were “truly exceptional,” demonstrating a statistically significant lowering of blood pressure in the patient population over multiple weeks
There is an established link between hypertension and vascular dementia, along with hypertension being twice as frequent in people with diabetes and hypertensive patients being at greater risk of developing diabetes
The success of these two studies will draw Lexaria closer to tapping into the dementia drug market, which is projected to hit $32.3 billion by 2030, and the diabetes drug market, which is expected to reach $82.92 billion by 2027

Lexaria Bioscience (NASDAQ: LEXX) just announced two notable studies, DEM-A22-1, and DIAB-A22-1, on dementia and diabetes, respectively, scheduled for completion in January 2023. The studies seek a deeper understanding of the company’s patented DehydraTECH(TM)-processed CBD for its potential therapeutic utility against both conditions (https://cnw.fm/5cLyS).

According to John Docherty, Lexaria’s President and Head of Research, these studies will build on the just-concluded hypertension clinical study whose results he referred to as “truly exceptional.” The study demonstrated a statistically significant lowering of blood pressure in the patient population over…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Animal Study to Evaluate Potential Therapeutic Effect of DehydraTECH-CBD on Dementia

November 23, 2022

November 23, 2022 08:05:00

Lexaria Bioscience has launched DEM-A22-1, its first-ever study to investigate whether its patented DehydraTECH(TM)-processed CBD may have therapeutic use against dementia
The animal study will involve a total of 32 Long Evans rats and will involve a memory assessment test that will be utilized to investigate whether CBD enables cognitive performance enhancements
Previous independent studies have shown that CBD prevents the development of a social recognition deficit, a symptom frequently reported in Alzheimer’s disease patients, and is linked to memory impairment
The laboratory work is expected to complete January 2023, with data and reporting to follow likely in April 2023

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is working on implementing its commercial strategies around the highly patented DehydraTECH(TM) drug delivery technology, with these strategies firmly anchored in and driven by R&D studies. According to company CEO Chris Bunka’s letter to shareholders, the company’s plans for 2022 included the launch and completion of several major applied studies as well as many smaller programs (https://cnw.fm/1il5f).

In line with these plans, the company has so far launched – and announced the successful results of – its most comprehensive hypertension study yet, HYPER-H21-4 (https://cnw.fm/AQxd2), and has received an Independent Review Board (“IND”) approval to commence its planned human oral nicotine study…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off First-Ever Study on DehydraTECH-CBD for the Potential Treatment of Diabetes

November 21, 2022

November 21, 2022 08:50:00

In November 2021, Lexaria laid out its plans for several new and ongoing R&D programs, among them hormone replacement, dementia, rheumatoid disease, and diabetes
The company has since begun its DIAB-A22-1 study program on the effectiveness of the patented DehydraTECH(TM)-processed CBD for the potential therapeutic utility against diabetes
Lexaria is optimistic that the study will yield some notable results, particularly with DehydraTECH-CBD having met primary safety and efficacy objectives from its HYPER-H21-4 clinical study on the potential treatment of hypertension
So far, CBD has shown some ability to reduce the incidence of diabetes in mice, and Lexaria looks to build on these findings and investigate DehydraTECH’s overall effectiveness for the potential treatment of the disease among human patients
DIAB-A22-1 marks a notable milestone for Lexaria and is a testament to the company’s commitment to advancing its efforts to address unmet patient needs and create shareholder value

In November 2021, Lexaria Bioscience (NASDAQ: LEXX), a global leader in enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs, announced its plans for several new and ongoing research and development (“R&D”) programs on its patented DehydraTECH(TM) technology for the 2022 calendar year. The study areas included hormone replacement, dementia, rheumatoid disease, and diabetes (https://cnw.fm/SDZ4W).

On November 8, 2022, Lexaria announced that the study program, DIAB-A22-1 began on schedule, making it the company’s first-ever study to investigate whether its DehydraTECH-processed cannabidiol (“CBD”) may potentially have therapeutic utility against…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Zacks SCR Uses Lexaria Bioscience Corp. (NASDAQ: LEXX) HYPER-H21-4 Study to Support $15 Share Valuation

November 11, 2022

November 11, 2022 08:05:00

Lexaria’s HYPER-H21-4 human clinical study was a success, producing favorable results in treating hypertension when comparing the company’s patented DehydraTECH(TM) CBD with a placebo
According to a Zacks SCR report, the findings support their $15 share valuation of the company
Zacks expects Lexaria to penetrate global markets for hypertension, nicotine delivery and antiviral products
The hypertension drug market is expected to grow to over $34 billion through 2030, with North America anticipated to hold 35% of the market share

According to the World Health Organization (“WHO”), approximately 1.13 billion people worldwide suffer from hypertension (high blood pressure), with only one in five being treated or under control. The hypertension drug market size in 2021 was valued at $25,394 million and is expected to grow at a CAGR of 3.4% through 2030, resulting in an estimated value of $34,072 million. The North American market is expected to lead with more than 35% of the world market share (https://cnw.fm/H78Yx).

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently released impressive results from its fourth and most comprehensive hypertension study, HYPER-H21-4. The study, structured as a randomized, double-blind, placebo-controlled cross-over study, dosed 66 male and…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Aiming to Address Unmet Patient Needs of Hypertensive Patients

November 8, 2022

November 8, 2022 09:35:00

Lexaria just completed its HYPER-H21-4 human clinical hypertension study, posting a sustained drop in blood pressure in normally active hypertensive patients
With the success of this study, the company is working towards an IND application to seek FDA approval for its patented DehydraTECH(TM)-enabled CBD capsule formulation.
47% of adults live with hypertension but only 24% of them have it under control
With its DehydraTECH-CBD, Lexaria hopes to not only address the severe unmet patient need associated with hypertension but also tap into a market that is set to be valued at $34 billion by 2030

Lexaria Bioscience (NASDAQ: LEXX), a global leader in enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs, is looking to push the conversation about high blood pressure.

Lexaria continues to move forward, most recently with the success in its latest human clinical study, HYPER-H21-4. The study may be the first to evidence a sustained drop in blood pressure in normally active patients following multiple weeks of oral cannabidiol (“CBD”) therapy using the company’s…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Zero Adverse Effects from Successful HYPER-H21-4 Study of DehydraTECH(TM)-CBD for High Blood Pressure

November 4, 2022

November 4, 2022 09:35:00

The CDC reported more than 670,000 annual deaths in the United States with high blood pressure as a primary or contributing cause
Lexaria’s patented DehydraTECH(TM) technology has been shown, through HYPER-H21-4 study, to decrease high blood pressure in subjects through DehydraTECH-CBD-enabled dosing
The global antihypertension drug market was valued at over $22.5 billion in revenue in 2018 and is expected to grow at a CAGR of 3.1%, resulting in a market of over $28.7 billion by 2026

In the United States, uncontrolled high blood pressure is common among adults – with only one in four having the condition under control. According to the Centers for Disease Control and Prevention (“CDC”), in 2020, more than 670,000 deaths in the United States had high blood pressure as a primary or contributing cause (https://cnw.fm/oH9ZC). Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced that its human clinical study HYPER-H21-4 may be the world’s first study to evidence a sustained drop in blood pressure in normally active patients following multiple weeks of oral cannabidiol (“CBD”) therapy using the company’s patented DehydraTECH(TM)-enabled CBD capsule formulation.

According to company CEO Chris Bunka, this is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit. Additionally, DehydraTECH also demonstrated excellent safety and tolerability results and no adverse changes in…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

India Globalization Capital Inc. (NYSE American: IGC) Is ‘One to Watch’

November 2, 2022

November 2, 2022 08:50:00

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia
As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC based formulation on Alzheimer’s patients
The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines
Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S.

India Globalization Capital (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (“THC”) compound plus another molecule…

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://cnw.fm/IGC

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Maintains Late 2022/Early 2023 for Full IND Application for DehydraTECH-CBD

November 2, 2022

November 2, 2022 08:05:00

Lexaria, through its patented DehydraTECH(TM) technology, is improving the bioavailability of pharmaceuticals and therapeutics (in part) by bypassing first-pass-liver processing, thereby achieving an improved speed of onset, and brain absorption of APIs
Hypertension currently affects nearly 50% of all American adults, with the American Heart Association describing it as a “silent killer”, and is now being studied for its effects during pregnancy
The company has received positive feedback for its pre-Investigational New Drug meeting from the FDA and has reported that it remains on track to file its full IND application by late 2022/early 2023
It looks to capitalize on the growth of the antihypertension market, which is set to hit $40 billion by 2031, up from $30.2 billion in 2021

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has been on an aggressive push to perfect its potential hypertension treatment, building on its patented DehydraTECH(TM) technology. Through improving the bioavailability of pharmaceuticals and therapeutics (in part) by bypassing first-pass-liver processing, Lexaria can achieve an improved speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”), which is integral to the overall treatment of conditions including but not limited to hypertension.

The American Heart Association (“AHA”) has described hypertension or high blood pressure as a “silent killer,” with nearly 50% of American adults having the condition (https://cnw.fm/P7rGD). In addition, hypertension during pregnancy comes with severe short-term risks for both mothers and their…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Tampa Alternative Products Expo To Offer A Festive Vibe Amongst Business Networking

November 1, 2022

November 1, 2022 11:05:00

Exhibitors, speakers, businesses, CBD and alternative products vendors, and researchers, are all invited to attend the Tampa Alternative Products Expo 2022 at the Tampa Convention Center. With over 10,000 attendees, 300+ vendors, and 20+ speakers per event, the Expo will exude a festival-like vibe for Tampa’s CBD, cannabis, and vape communities.

The event is organized by ZJ Events, with a reputation for managing the nation’s largest CBD & Hemp Summits. The Alt Pro Expo team has expanded into the alternative products sector, which is currently disrupting traditional markets. This product category includes kratom, nootropics, vapes and…

To learn more, please visit https://cnw.fm/f6qpK.

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves to Address Adverse Effects of Hypertension with DehydraTECH(TM) – CBD

October 31, 2022

October 31, 2022 08:05:00

Lexaria is a drug delivery technology company developing DehydraTECH-CBD as a prospective registered treatment for hypertension and potentially other disease states beyond hypertension
The company has undertaken multiple de-risking hypertension studies that have not only evidenced that DehydraTECH-CBD is safe and well tolerated, but have also shown that it reduces blood pressure and arterial stiffness
Hypertension is a leading contributor to deaths in the United States, damaging organs such as the heart, brain, and kidneys, yet only a tiny proportion of patients have it under control

Hypertension, an area of interest and focus for drug delivery technology company Lexaria Bioscience (NASDAQ: LEXX), has many harmful effects on the body, its organs, and overall personal health. Hypertension, or high blood pressure is a condition characterized by consistent exertion of elevated pressure – at least 130/80 mmHg – on blood vessels. This pressure, analyses have shown, causes the walls of blood vessels to become less stretchy or elastic, narrowing their internal cross-sectional area and ultimately damaging them (https://cnw.fm/cVeTX).

As a result, blood flow drastically reduces, and in a cascade of events, the flow of oxygen to the heart also declines. This has been linked to heart disease, heart attack, and heart failure. Nonetheless, the reduced blood flow does not only impact the functionality of the heart but also other organs, including the…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Potential Hypertension Medication Poised to Reduce Risk of Blood-Pressure-Induced Dementia, Cognitive Decline

October 25, 2022

October 25, 2022 08:50:00

Lexaria Bioscience is a global innovator in drug delivery platforms that has developed the patented DehydraTECH(TM) technology for improved delivery of bioactive compounds
The company is currently evaluating DehydraTECH-processed CBD as a potential treatment for high blood pressure
Long-term studies have shown that high blood pressure can increase the risk of developing dementia in later life
Experts, however, believe that hypertension medication could slow the pace of the cognitive decline
In addition to helping hypertension patients keep their condition under control, Lexaria’s DehydraTECH-CBD, which has so far been shown to be safe and well tolerated, could potentially help reduce the risk of dementia

Blood pressure or BP typically refers to the pressure exerted by circulating blood against the walls of blood vessels, particularly large arteries and veins. This pressure fluctuates throughout the day depending on the activity in which one engages. However, in some instances, it can consistently cross the normal threshold, a condition known as high blood pressure or hypertension. Usually, and based on a 2017 guideline, a person is said to have high BP when the top reading on the blood pressure monitor, which represents the systolic blood pressure, is greater than 130 mmHg while the bottom reading, which denotes the diastolic pressure, is above 80 mmHg (https://cnw.fm/NVuKL).

The constant exertion of elevated pressure on blood vessels damages them by making them less elastic. According to the Centers for Disease Control (“CDC”), this decreases the flow of blood and oxygen to the heart and other body organs. And it is this depressed blood flow that causes progressive damage to…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program Seeking to Provide Safe, Well-Tolerated, Effective Antihypertensive Medication Amid Continued Reports of Suboptimal Adherence to Existing Treatments

October 17, 2022

October 17, 2022 08:50:00

Lexaria Bioscience, a global innovator in drug delivery technology, has developed a potential treatment for hypertension using the company’s patented DehydraTECH(TM) platform, now shown in several human studies to reduce blood pressure and arterial stiffness
Lexaria’s antihypertensive drug development program comes at a time when researchers are documenting poor control of hypertension among both men and women, partly due to suboptimal adherence to existing antihypertension medication
Reasons advanced for the suboptimal adherence include lack of awareness or treatment, increased number of prescribed medications, and major adverse effects of the prescribed drugs
Lexaria has so far shown that its DehydraTECH-CBD is not only effective but also well tolerated and is planning to undertake registered clinical trials in pursuit of the FDA’s approval of the drug candidate

A recent research article published in the Journal of the American Heart Association (“AHA”) unearths data that suggests poorly controlled hypertension among both men and women (https://cnw.fm/q4IM3), a problem global innovator Lexaria Bioscience (NASDAQ: LEXX) is keen on solving.

The researchers, who sought to describe gender-differential disease patterns and results of more than 20.6 million emergency department encounters in the United States from 2016 to 2018, made several observations. Firstly, most ED cardiovascular (“CVD”) visits in the sample were due to hypertensive…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Using Patented DehydraTECH(TM) Technology to Fight America’s Silent Killer – Hypertension

October 13, 2022

October 13, 2022 08:05:00

Three out of four adults living with hypertension do not have the condition under control, putting them at risk for other serious complications
Lexaria’s proposed therapy for hypertension is the highly efficient DehydraTECH-CBD, which has presented with no serious adverse side effects in test participants
Dominated by the North American market, the global antihypertension drug market accounted for $22,557 million in 2018 and is expected to reach $28,797 million by 2026

In the United States, over 121.5 million adults are affected by high blood pressure – with statistics stacked against people of color, those with a family history of high blood pressure, heart disease, stroke, or kidney disease, and women who experienced blood pressure problems during pregnancy. According to the American Heart Association, high blood pressure is defined as a systolic pressure of 130 or higher and a diastolic pressure of 80 or higher that stays high over a period of time (https://cnw.fm/dbCLN).

For some, managing high blood pressure is as simple as changing daily habits or being proactive about monitoring it if there is a history or predisposition to the disease. Early detection can protect the brain, reducing the risk of stroke, dementia, and other vascular diseases that affect the…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Offering Solutions to Growing Hypertension Problem Worldwide

October 11, 2022

October 11, 2022 08:50:00

Hypertension affects nearly half of all adults in the United States – 47% or 116 million people, some of which are medication-resistant
A recent study from the University of Toledo College of Medicine and Life Sciences concluded gut bacteria might be the cause of medication-resistant hypertension – as demonstrated in rats used to conduct the study
Lexaria’s patented DehydraTECH(TM) technology offers a viable solution for hypertension drug administration and has been received favorably by the FDA during a pre-Investigational New Drug meeting

Hypertension, or high blood pressure, remains one of the world’s most deadly health problems, considered a silent killer because it presents with no symptoms. Nearly half of the adult population in the United States (47% or 116 million) have been diagnosed with hypertension, as defined by having systolic blood pressure greater than 130 mmHg or diastolic blood pressure greater than 80 mmHg or taking medication for the condition (https://cnw.fm/JjXeS). Within this category of adults, some fall into a medication-resistant form of hypertension.

A new study by The University of Toledo College of Medicine and Life Sciences has shown that gut bacteria may be a culprit for medication-resistant hypertension, solving an elusive mystery that has plagued many Americans and their physicians. The study, conducted using lab rats, concluded that…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Working to Address Declining Antihypertensive Intensification and High Prescription Abandonment Rates, with DehydraTECH-CBD

October 7, 2022

October 7, 2022 10:20:00

Lexaria is a global innovator in drug delivery platforms developing DehydraTECH-CBD as a potential treatment for hypertension
A 2022 study documented a decline in the percentage of patients receiving appropriate treatment intensification over the last ten years
This decline has been attributed to, among other possible reasons, the side effects of antihypertensive drugs
At the same time, only 24% of adults with hypertension have the condition under control, a statistic attributable to the medications’ troublesome side effects
Lexaria’s investigations of its DehydraTECH-CBD have so far presented favorable safety and tolerability data, meaning its drug candidate could offer reprieve to millions looking for antihypertensive drugs with little or no side effects

A recent study published in the American Heart Association (“AHA”) journal Hypertension concluded that “appropriate treatment intensification for older adults with hypertension in the United States was suboptimal over the past decade” (https://cnw.fm/jlEvr). The study results showed the percentage of patients receiving appropriate treatment intensification – described as the addition of an antihypertensive drug to the patient’s care for high blood pressure – had declined over the ten years across all the three blood pressure targets used.

The study sampled adults aged 60 and older who visited their primary care provider and previously had been diagnosed with hypertension, with the researchers focusing on patients that had undergone…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Expands Global Distribution Network to Three Industry-Leading Countries; Wins Award for Best M&A Deal at the 2022 Benzinga Cannabis Capital Conference

October 4, 2022

October 4, 2022 09:35:00

Flora just announced the first successful export of Colombian high-CBD dried cannabis flower to Switzerland and the Czech Republic, as well as CBD isolate to the United States
Luis Merchan, the company’s CEO, has described this as a “major milestone,” one that further defines the company’s revenue pipeline
He pointed out the increasing demand for Flora’s high-quality, high-margin flower and derivatives from its cultivation operation in Colombia, terming it as a testament to the Flora team’s ability to execute in a very complex global regulatory environment
Flora also earned the Best M&A Deal award at Benzinga’s 2022 Cannabis Capital Conference in Chicago, an award that recognized the company’s strategic M&A objectives, including acquiring products, expertise, expanding distribution, and customers

On September 26, Flora Growth (NASDAQ: FLGC) announced the first successful export of Colombian high-CBD dried cannabis flower to Switzerland and the Czech Republic, as well as CBD, isolate to the United States. Luis Merchan, Chairman and Chief Executive Officer (“CEO”) of the company, described this as a “major milestone,” one that further defines Flora’s revenue pipeline. The company also launched its commercial website, where interested buyers can expedite the processing of orders and learn about the company’s cultivation and growth practices (https://cnw.fm/l07N0).

With the global CBD market having achieved impressive growth thus far and showing even greater potential growth in the coming years, Flora is positioning itself as a key industry player, looking to take…

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Focusing on Multiple Mainstream Applications of Its Disruptive Patented DehydraTECH(TM) Technology

October 3, 2022

October 3, 2022 09:05:00

Lexaria is the drug delivery platform innovator behind the disruptive, patented DehydraTECH(TM) technology
DehydraTECH is designed to enhance the performance of fat-soluble active pharmaceutical ingredients (“APIs”), molecules, and drugs by increasing their bioavailability
Through animal and human studies, Lexaria has shown that DehydraTECH increases the bioavailability of antiviral drugs, CBD, oral nicotine and more
The company is focusing on multiple mainstream applications of its technology that rerrcould address serious unmet patient needs
Lexaria is currently keen on developing a potential treatment for hypertension

Last summer, drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX) announced a review of its successful 2021 antiviral drug program. The program, which aimed to determine whether the processing of leading antiviral drugs using its patented DehydraTECH could exhibit evidence of superior oral absorption relative to controls; whether DehydraTECH processing of these compounds would preserve the expected viral inhibitory performance; and whether DehydraTECH does not alter or degrade the drug molecules chemically, met all three of these objectives (https://cnw.fm/Nncql).

Lexaria specifically probed the bioavailability of five DehydraTECH-processed antiviral drugs for SARS-CoV-2, HIV/AIDS, and other infectious diseases from three drug classes, evidencing significant gains with up to a three-fold increase in oral drug delivery into the…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Addressing Hypertensive Patients’ Concerns with DehydraTECH-CBD

September 29, 2022

September 29, 2022 09:05:00

Lexaria is a global innovator in drug delivery platforms whose lead technology is DehydraTECH(TM)
Studies have shown that DehydraTECH increases the intestinal bioabsorption of bioactive compounds by as much as 27 times, hence resulting in greater bioavailability; pre-clinical and human studies have demonstrated that DehydraTECH-CBD enables absorption increases of between 100% and 500% The studies have also shown that DehydraTECH-CBD results in a rapid and sustained drop in blood pressure among hypertension patients
Lexaria, which believes there is a significant unmet demand for cost-effective hypertensive treatments with few or no side effects, is working toward commercializing DehydraTECH-CBD to satisfy this demand

Currently, roughly 20% of people diagnosed with hypertension take medication, with the remaining majority noting that the medications’ side effects substantially outweigh the benefits. This has often constrained the fight against hypertension, the most common cardiovascular disease worldwide, which affects more than one billion people and is associated with long-term morbidities such as heart disease, stroke, and even death.

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, believes the hesitance or refusal to take medication presents a significant unmet demand for more tolerable, cost-effective anti-hypertensive treatments and has been working to bring such treatments to the…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Provide Bioavailable Oral Treatment for Hypertension, Mitigate Effects of High Blood Pressure

September 21, 2022

September 21, 2022 08:05:00

Lexaria is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”)
The company has developed the patented DehydraTECH(TM) drug delivery technology, which has been shown to deliver more API at a faster rate than controls
Lexaria’s DehydraTECH pipeline includes DehydraTECH-CBD for the treatment of hypertension
Through pre-clinical studies, DehydraTECH-CBD has been shown to decrease systolic blood pressure among hypertensive volunteers
The company intends to file an Investigational New Drug (“IND”) application and has already received confirmation that the FDA agrees with its proposed abbreviated pathway under section 501(b)(2)

Oral delivery remains the preferred route of administering drugs among cooperating and conscious patients. But some drugs do not have the desired physicochemical and pharmacokinetic characteristics that favor oral administration, an issue that is linked to poor bioavailability. This has often led to the use of other routes or prompted the administration of higher doses, with the latter causing toxicity concerns and risks tied to erratic and unpredictable responses. These challenges, coupled with the fact that more than 90% of therapeutic compounds are known to possess oral bioavailability limitations, have necessitated research that explores ways to enhance oral drug bioavailability (https://cnw.fm/5fM38).

The research has been spearheaded by scholars and scientists as well as companies such as Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms. A biotechnology company focusing its attention and resources on pursuing the enhancement of the bioavailability of a…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX), Growing its Market Share, One Patent at a Time

September 16, 2022

September 16, 2022 08:50:00

Lexaria’s development of its patented DehydraTECH(TM) technology since 2014 has yielded 27 patents in Australia, the United States, the European Union, Japan, India and Mexico with approximately 50 additional patents pending around the world
Its latest patent, granted in Mexico, applies a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a variety of ready-to-drink consumer retail beverage products
Lexaria remains committed to advancing its research and expanding the indications and efficacy of its DehydraTECH technology, as it looks to benefit from the CBD industry, projected to be valued at $111.8 billion by 2030, and the cardiovascular drugs market, projected to be valued at $107.8 billion by 2025

Since Lexaria Bioscience (NASDAQ: LEXX) began the development of its industry-leading DehydraTECH(TM) technology back in 2014, the company has remained steadfast in its goal to improve the way active pharmaceutical ingredients (“APIs”) enter the bloodstream. Moreover, as a global innovator in drug delivery platforms, the company has not shied away from advancing its research to cut across various health conditions, including but not limited to hypertension, epilepsy, diabetes and dementia, among others.

These efforts have yielded 27 granted patents around the world since 2014, with approximately 50 additional patents pending. It also has national filings in over 40 jurisdictions with the highest commercial potential, reflecting the company’s commitment to creating shareholder value and pushing its…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Strengthens Board of Directors to Boost Efforts toward Regulatory Approval of Potential Treatment for Hypertension

September 14, 2022

September 14, 2022 08:05:00

Lexaria Bioscience is a global innovator in drug delivery platforms whose lead technology, DehydraTECH, has been shown to increase the bioavailability of APIs
The company recently announced that Catherine Turkel, PharmD, Ph.D., has joined its board of directors
Dr. Turkel, who brings over 20 years’ experience, has previously formulated Food and Drug Administration (“FDA”) registration and commercial strategic plans, as well as led global development programs for pharmaceutical and biologic treatments
Dr. Turkel will lend her drug registration experience and regulatory expertise to Lexaria at a time when the company is journeying toward regulatory approval for DehydraTECH-CBD, its drug candidate for the treatment of hypertension
Lexaria recently had a pre-IND meeting with the FDA, where it received positive feedback

Companies should bring on board members with strategic growth experience who have “been there, done that,” a June 2022 article in Forbes advises (https://cnw.fm/MUABF). Strategic growth, the article observes, “is one of the most important areas of governance for boards. The more experience on a board, the more efficient you are at developing tried and tested growth strategies… Members with experience down certain paths can guide a company to anticipate and avoid known obstacles, helping to accomplish goals faster.”

As Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, charts the long path toward regulatory approval for DehydraTECH(TM)-processed cannabidiol (“CBD”), a prospective treatment for hypertension, the importance of bringing on board members with…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Acquires 27th Worldwide Patent Applying to a Range of APIs in Ready-to-Drink Consumer Retail Beverage Products

September 12, 2022

September 12, 2022 08:05:00

Lexaria’s Mexican patent “Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Ingredients” joins the ranks of previously issued patents in Australia, India, Japan and the EU
The patent allows the company to provide value in gaining regulatory approval for its DehydraTECH(TM)-enabled CBD for multiple indications in the health and wellness field
Additional claims to Mexican patent #390001 include Alzheimer’s disease, Parkinson’s disease, schizophrenia, Human Immunodeficiency Virus (“HIV”) dementia, obesity, hepatic diseases, diabetes, appetite disorders, cancer chemotherapy, benign prostatic hypertrophy, irritable bowel syndrome, biliary diseases, ovarian disorders, marijuana abuse, and alcohol, opioid, nicotine, or cocaine addictions
The global market of CBD for health and wellness purposes was valued at $4.9 billion in 2021 and is expected to grow to $47.22 billion by 2028

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced that the Company has received its 27th worldwide patent, granted in Mexico under registration #390001. The patent from Lexaria’s third patent family, “Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents,” has already been issued in Australia, India, and Japan (https://cnw.fm/bsY27). The patent applies to a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a wide variety of ready-to-drink consumer retail beverage products.

Lexaria’s latest patent provides value to the company through its continued pursuit of gaining regulatory approval for its patented DehydraTECH(TM)-enabled cannabidiol (“CBD”) for the treatment of hypertension in regulated pharmaceutical applications. This has produced the claims necessary for the…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Quest to Find Hypertension Treatment Promising With DehydraTECH(TM)’s Ability to Boost Bioavailability

September 6, 2022

September 6, 2022 08:50:00

Lexaria, a global innovator of drug delivery platforms is looking to provide a FDA registered hypertension treatment with its patented DehydraTECH technology
The company’s efforts are encapsulated in its DehydraTECH-CBD that has been shown to lower blood pressure as well as reduce arterial stiffness
Although hypertension is a devastating condition that can cause not only life-threatening illnesses but also death, only about 53% of Americans with the condition have it under control
A Harvard Health article notes that the remaining portion (47%) are not able to control the disease because they are discouraged by medications’ side effects
Lexaria’s DehydraTECH-CBD may well be the solution such individuals seek, but for now, the company is following the regulatory pathway to eventual drug approval

Hypertension causes life-threatening conditions such as stroke, heart attacks, coronary artery disease, and heart failure. But even more concerning, the condition leads to death. In 2020, the U.S. Center for Disease Control (“CDC”) reported that high blood pressure claimed more than 670,000 lives in the U.S. (https://cnw.fm/1PKhk). Globally, hypertension claims an estimated 7.5 million lives annually, according to the World Health Organization (“WHO”) (https://cnw.fm/UCJeh).

Despite these devastating consequences and statistics, only about half (53%) of Americans living with high blood pressure have it under control, a problem that a Harvard Health article attributes to, among other common reasons, the fact that many stop taking their.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces the Availability of a Broadcast titled, “The Power of Science to Stop a Killer”

August 30, 2022

August 30, 2022 08:50:00

Lexaria’s latest broadcast highlights the company’s progress in finding a potential solution for hypertension treatment while also pointing out why such a solution is much needed at this point
Since the company began developing its patented DehydraTECH(TM) technology in 2014, it has made significant progress in its clinical studies, even as it currently focuses on human clinical research to evaluate the tolerability, safety, and efficacy of its solution for hypertension treatment
Lexaria expressed its confidence in its proposed solution, noting that it will not only be a safer but also better-tolerated drug candidate, unlike current alternatives in the market whose side effects far outweigh their benefits
The company looks to capitalize on the growing global anti-hypertensive drugs market, which is projected to hit $27.81 billion in value by 2025, and maintains that should it sustain the results achieved in recent hypertension studies, then it could be looking at mega-drug status ($1 billion per year) in the hypertension market

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released its latest addition to a growing body of corporate communication pieces in its line-up. Titled “The Power of Science to Stop a Killer,” this recent broadcast highlights the company’s progress in finding a potential solution for hypertension treatment, while also pointing out why a solution is much needed at this point (https://cnw.fm/6E6Dy).

Lexaria’s flagship offering, its patented DehydraTECH(TM) technology, has proven to improve ways through which active pharmaceutical ingredients (“APIs”) enter the bloodstream, primarily by promoting healthier oral ingestion methods and increasing the effectiveness of…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program and Recent FDA Confirmation Position It for Favorable Valuation

August 26, 2022

August 26, 2022 10:20:00

Lexaria is a global innovator of drug delivery platforms, including its patented DehydraTECH(TM) technology
The company recently released information that would help its stakeholders research and understand how biotech and pharmaceutical companies are valued
Based on some of the methodologies used in valuation, Lexaria is positioned favorably as its DehydraTECH-processed CBD for the treatment of hypertension has successfully reached the IND application stage, with the program recently receiving an additional boost
The FDA agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway, an abbreviated pathway, for its hypertension program

As a follow-up to recent coverage by Zacks Small-Cap Research, which valued the company at $15.00 (https://cnw.fm/obZ1e), global innovator Lexaria Bioscience (NASDAQ: LEXX) provided information to its stakeholders that would help them conveniently research and understand different non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies.

“Valuation of equities is a complex task with innumerable risks and rewards that include far-reaching macro events as well as company-specific developments. It is nearly impossible to foresee all risks and rewards, but underlying logic-based evaluation is one way to provide a realistic framework of…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Delighted About Well-Received DehydraTECH-CBD Proposals by the FDA; Maintains Late 2022/Early 2023 Target For Complete IND Application

August 19, 2022

August 19, 2022 08:50:00

Lexaria’s successful HYPER-H21-2 human clinical study, whose results were announced in the first week of September 2021, laid the groundwork for the company’s patented DehydraTECH(TM)-processed CBD NDA
Chris Bunka, the company’s CEO, referred to the results as “statistically significant,” ultimately kickstarting the IND application process with the FDA
Lexaria has since received a full written positive response from the FDA on its DehydraTECH-CBD, agreeing to the company’s proposal to pursue the 505(b)(2) NDA regulatory pathway
As a result of the favorable FDA response, Lexaria expects to remain on track to file its full IND application, 6-9 months sooner than if the FDA had required modifications in Lexaria’s current IND-enabling work plan, and Its management is confident that maintaining the current trajectory could allow the company to achieve $1 billion per year in the hypertension market, even making it one of the most effective registered pharmaceutical treatments for hypertension in the world

In the first week of September 2021, Lexaria Bioscience (NASDAQ: LEXX) announced its most recent results, at the time, from its HYPER-H21-2 human clinical study on the overall effectiveness of its patented DehydraTECH(TM)-processed CBD on blood pressure. The successful study would play an integral role in the company’s eventual New Drug Application (“NDA”), with Chris Bunka, the company’s Chief Executive Officer (“CEO”), terming the results as “statistically significant” (https://cnw.fm/X9wKM).

The success of multiple human studies investigating DehydraTECH-CBD for hypertension prompted Lexaria to formally announce the process of an Investigational New Drug (“IND”) application filing with the United States Food and Drug Administration (“FDA”) to list DehydraTECH-CBD as a…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Four Partnerships, Boosts ‘Revenue Picture’

August 16, 2022

August 16, 2022 08:05:00

Lexaria Bioscience, a global innovator in drug delivery platforms, recently announced partnerships with Premier Wellness Science Co., BevNology, AnodGen Bioceuticals, and Valcon Medical A/S
According to coverage by Zacks Small-Cap Research, who value Lexaria at $15 per share, the most impactful of these partnerships is with Premier because the company is expected to start paying license fees in early September
In a June 7 Fireside Chat, Lexaria Chair and CEO Chris Bunka disclosed that the company is capitalizing on partnerships with “national players in different areas of the world” to improve its “revenue picture” and offset its cash burn
In the longer term, the company is targeting milestone payments from large national and international consumer companies and pharmaceutical organizations

In a June 7 Fireside Chat hosted by John D. Vandermosten, CFA, of Zacks Small-Cap Research (“SCR”), Lexaria Bioscience (NASDAQ: LEXX) Chair and CEO Chris Bunka expressed hope that the then-ongoing negotiations with “national players in different areas of the world” would yield contracts that would significantly improve its revenue (https://ibn.fm/qhlo1). The negotiations led to separate announcements that form the basis of Zacks SCR’s latest coverage of the company, who value Lexaria at $15 per share (https://ibn.fm/OvOaJ).

“Lexaria experienced a substantial amount of activity on both the drug development front and in closing agreements with partners since the end of the fiscal second quarter,” Zacks notes in its coverage (https://ibn.fm/sGXzP). “The company announced four material partnerships in June that will provide…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to DehydraTECH-CBD FDA Evaluation Following Successful Dosing in Multi-Week HYPER-H21-4 Human Clinical Study

August 12, 2022

August 12, 2022 08:05:00

Lexaria just completed dosing for its HYPER H21-4 human clinical study that dosed 64 patients aged between 40 and 70 with measured elevated blood pressure, stage 1 and stage 2 hypertension
HYPER-H21-4, Lexaria’s most ambitious hypertension clinical study yet, builds on the success of HYPER-H21-1 and HYPER-H21-2, both completed in 2021
It explores the use of the company’s patented DehydraTECH(TM) technology in the potential treatment of hypertension
Lexaria is confident that the additional data sets collected over the course of the study will lead to supplementary applications for DehydraTECH while providing valuable additional insights into the long-term health benefits of this compound that might otherwise remain undetected

In November 2021, Lexaria Bioscience (NASDAQ: LEXX) announced its most ambitious hypertension study yet, HYPER-H21-4. The goal of the study, according to Lexaria’s Chief Executive Officer (“CEO”), Chris Bunka, was to “Support the company’s goals related to pursuit of regulatory approvals for DehydraTECH-CBD for potential use as a treatment for high blood pressure,” (https://cnw.fm/8fXrT).

At the close of the year, Lexaria received independent Review Board (“IRB”) approval ahead of schedule, which marked a significant milestone for the company. It would set the stage for the commencement of the study in the year 2022 while allowing Lexaria to explore the full potential of its…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Generation of CBD Products Under “Ko” Branding by Japanese Licensee Premier Wellness Science Co., Ltd.

August 9, 2022

August 9, 2022 08:50:00

Lexaria’s patented DehydraTECH(TM) has 26 granted patents worldwide, including four in Japan
Lexaria stands to gain substantial revenue through the licensing of DehydraTECH technology across minimum quarterly payments for license use by Premier and royalties for products sold
By 2028, the CBD market is expected to reach US$47.22 billion, driven by increased demand for CBD use in health and wellness

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms and developer of the patented DehydraTECH(TM) technology for the delivery of fat-soluble molecules and drugs, has announced that Japanese Licensee, Premier Wellness Science Co., Ltd., has officially launched the first generation of its new cannabidiol (“CBD”) products under the brand, “Ko,” on July 21, 2022, for the Japanese consumer market (https://cnw.fm/Pm6hK). The exclusive rights between Premier and Lexaria are subject to two previously issued licenses for using DehydraTECH technology in Japan for non-pharmaceutical cannabinoid products. As of July 28, 2022, Lexaria has been granted 26 patents worldwide.

Under the terms of the license agreement with Lexaria, Premier purchased rights to the company’s DehydraTECH technology for use in the non-pharmaceutical market for CBD and hemp ingredients in oral liquid and non-liquid product forms, including topical, hair-care, lip-care, and…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pending Start of Human Nicotine Study, NIC-H22-1, Leveraging Fast-Growing Global Nicotine Pouches Market

July 20, 2022

July 20, 2022 09:35:00

Lexaria Bioscience Corp. expects the upcoming human nicotine study to produce evidence that its patented DehydraTECH(TM) technology can enhance oral-tissue absorption with reduced negative experiences
Data collected from animal study NIC-A21-1 showed that DehydraTECH enhanced oral nicotine pouches delivered peak nicotine levels in the bloodstream of animals 10x to 20x faster than the control
The global nicotine pouches market was valued at $2.33 billion in 2020 and is expected to reach $21.84 billion by 2027, being one of the fastest growing segments in the nicotine industry
Lexaria’s pipeline addresses serious unmet patient or consumer needs with greater market potential, addressing multiple mainstream applications in cannabinoids, oral nicotine, antiviral therapies, phosphodiesterase inhibitors, and other APIs

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the pending start of an upcoming human nicotine study, NIC-H22-1. The company expects to evidence that processing purified nicotine with its patented DehydraTECH(TM) technology leads to enhanced oral-tissue absorption and reduced negative experiences. NIC-H22-1 is a minimum 36-person human pharmacokinetic randomized, double-blind, cross-over study comparing DehydraTECH-nicotine pouch performance to existing brands currently on the market, including ON! and Zyn (https://cnw.fm/Dy3BE).

The study’s primary objective is the objective data collection from blood samples that will evidence Tmax, Cmax, and AUC. Other study objectives include extensive subjective evaluations related to complaints of throat burn, user experience, and more. The nicotine test article ingredient manufacturing and…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Best-In Class Solution To Major Issue Affecting A Range Of Critical Drug Applications

July 18, 2022

July 18, 2022 08:50:00

Researchers have run into the issue of solubility of molecules intended for absorption, ultimately affecting drug effectiveness and inhibiting patient recovery
This has forced the exploration of new drug delivery technologies, with Lexaria’s patented DehydraTECH(TM) technology proving to be the most innovative, useful, and effective
DehydraTECH(TM) technology has seen application in oral nicotine for reduced risk, antiviral drugs for COVID-19 and other infectious diseases, PDE5 inhibitors, and CBD for hypertension
The recent expansion of the Cannadips Brand into Europe, Japan, and South Africa highlights the proliferation of DehydraTECH and a significant growth in its market share, particularly in the CBD space
Lexaria is excited about the expansion and anticipates additional growth in its technology’s adoption as time progresses

For a long time, the medical industry has sought ways to improve patient health by enhancing the delivery of therapeutic drugs to target sites. An especially critical problem researchers in this sector have encountered is the limited solubility of the molecules intended for absorption.

It is estimated that approximately 90% of preclinical drug candidates are low-solubility compounds. This presents a challenge regarding the compounds’ bioavailability and effectiveness of the drugs. The problem has led researchers to explore various drug delivery technologies, some of which have shown…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Licensee Expands Manufacturing Agreements to Include Europe, Japan, and South Africa

July 14, 2022

July 14, 2022 08:05:00

Lexaria’s patented DehydraTECH(TM) enhancement technology targets key market segments including nicotine replacement, CBD, cardiovascular and antiviral drugs, human hormones, and PDE5 inhibitors
DehydraTECH-enabled drug and consumer products provide faster delivery times, increased bioavailability, increased brain absorption, improved drug potency, lower administration costs, and mask unwanted tastes
The global CBD market was valued at $5.18 billion in 2021 and is expected to grow at a CAGR of 16.8% from 2022 to 2030, resulting in a revenue forecast of $22.05 billion by 2030

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced that Boldt Runners Corporation, licensee of its patented DehydraTECH(TM) technology and owner of the Cannadips Brand, has expanded its manufacturing agreements to include Europe, Japan, and South Africa. Cannadips CBD dip pouches are the leading cannabidiol (“CBD”) pouch in the United States. They are a tobacco-free and nicotine-free dip alternative that provides an effective way for consumers to enjoy CBD. Cannadips is sold in over 6,500 retail locations across the United States, including direct-to-consumer online purchases (https://cnw.fm/x4P1h).

Every tin of Cannadips product features DehydraTECH enhancement technology and results from longstanding collaboration and product design. “We are delighted with the expansion of the Cannadips brand outside of the USA. We continue to work with the Cannadips team on the infusion of…

Read M ore>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Enhances Bioavailability of Orally Administered APIs

July 12, 2022

July 12, 2022 09:35:00

Lexaria is a global innovator in drug delivery platforms
The company has developed the patented DehydraTECH(TM) technology that significantly improves the bioavailability of orally administered pharmaceuticals and therapeutics
Bioavailability is the fraction of a drug that reaches the site of action or systemic circulation
While drugs delivered intravenously are 100% bioavailable, drugs that have any other route of administration, such as oral, have reduced bioavailability
DehydraTECH enhances the bioavailability of APIs, in part, by bypassing first-pass liver processing

Global innovator Lexaria Bioscience (NASDAQ: LEXX) has built a reputation as a developer of drug delivery platforms, the most notable of which is the patented DehydraTECH(TM) technology. DehydraTECH is a formulation and dehydration processing method that modifies how the body detects and absorbs drugs, solving a glaring problem that has long affected orally administered drugs: low bioavailability.

Bioavailability indicates the fraction or rate of the initial dose of a drug that is successfully made available to the site of action or systemic circulation (blood supply to all body tissues) from where target organs can readily access. “Intravenous dosing is considered 100% bioavailable since the drug is…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Production Capabilities to Support Growing List of Business-to-Business Clientele

July 6, 2022

July 6, 2022 09:35:00

Lexaria is a global innovator in drug delivery platforms; its patented DehydraTECH(TM) technology improves the bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“API”)
Testing confirms that DehydraTECH-processed cannabidiol beverages maintained 93.4% and 78% potency of CBD a full year and two years after production, respectively
Lexaria recently signed two agreements with BevNology LLC, an Atlanta-based company with advanced capabilities that support best-in-class beverage formulations
The partnership, which also leverages Lexaria’s superior DehydraTECH-CBD nanoemulsification formulation and processing techniques, could make industry-leading beverage products a reality for many brands

In this year’s letter to shareholders, Lexaria Bioscience (NASDAQ: LEXX) Chair and CEO Chris Bunka acclaimed the company’s research and development achievements which had resulted in remarkable stability of DehydraTECH(TM)-processed cannabidiol (“CBD”) beverages. One year after production, Bunka wrote, “bottled consumer beverage contained a remarkable 93.4% potency of CBD. We also showed less than 1% variability of CBD potency within the beverage, a concept of critical importance when delivering drugs in an aqueous solution” (https://cnw.fm/H4ndc).

The latest data from stability testing undertaken 25 months after initial bottling show the product had higher variability but still retained an average 78% of originally formulated CBD. Additionally, the microbiologic purity and cleanliness of the product surpassed all requirements 25 months after…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

CanadianCannabisWire is part of the InvestorBrandNetwork.

Flora Growth Corp.’s (NASDAQ: FLGC) Management Confident in the Company’s Short, Medium, and Long-Term Growth Prospects

July 5, 2022

July 5, 2022 10:20:00

Flora just announced the repurchase of $5 million of its outstanding common shares
This repurchase aligns with its overall global expansion plan, and its move to grow its market reach
These moves by Flora assure shareholders of the company’s commitment to driving shareholder value and exploring various opportunities to do so

On June 16, 2022, Flora Growth (NASDAQ: FLGC) announced that its Board of Directors had authorized the repurchase of up to $5 million of its outstanding common shares. This came in the wake of the expiration of a one-year lockup period for specific shareholders who had acquired shares before the company’s Initial Public Offering (“IPO”).

While making the announcement, Luis Merchan, Flora’s Chairman and Chief Executive Officer (“CEO”), noted…

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Anticipates Continued Growth for Cannabis Operations Under New Colombian Administration

June 30, 2022

June 30, 2022 08:50:00

Flora Growth is a cannabis cultivator and distributor with a base of operations in Colombia’s fertile growing climate, capable of feeding the company’s expanding international supply chain
Colombia has undergone a number of regulatory changes in recent years as it emerges from the shadows of years-long drug wars and embraces a growing global acceptance of cannabis products
The South American country voted in a new presidential administration in June, and Flora Growth is applauding the president-elect’s continued openness to international cannabis trade
Flora Growth announced significant revenue growth during its year-end financial reporting in May, and the company stated it expects another 288 to 400 percent increase in revenues during the current year

Following nationwide elections that marked a historic change in Colombia’s presidency as well as its people’s social policy aspirations, emerging cannabis brand builder Flora Growth (NASDAQ: FLGC) is expressing optimism for its market opportunities, which are based on a growing cannabis cultivation operation in the South American country.

Longtime legislator Gustavo Petro, a sitting senator and previously Mayor of Bogota, was declared Colombia’s chief executive-elect June 19 after his remaining opponent in a runoff election conceded that Petro had won the majority of the vote in an orderly transfer of…

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

New Agreements Signed Between Lexaria Bioscience Corp. (NASDAQ: LEXX) and BevNology LLC; Pre-IND Meeting Request Filed with FDA

June 29, 2022

June 29, 2022 10:20:00

The two companies signed a manufacturing operating agreement and a commercial agreement
Lexaria sent a pre-IND meeting request letter to the US FDA and plans to file the full IND application in late 2022/early 2023
The FDA has acknowledged Lexaria’s pre-IND request and responded with conditions prior to the target date of July 30, 2022

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has recently announced signing two agreements with BevNology LLC, the product and development arm of InterContinental Beverage Capital (“IBC”), operating its state-of-the-art lab and manufacturing facility just outside of Atlanta, Georgia. This announcement only furthers Lexaria’s leverage of the market, with the company’s patented DehydraTECH(TM) technology having already been embraced by several consumer packaged goods brands, with availability in over 7,000 stores throughout the United States and Japan, including direct-to-consumer online retail portals (https://cnw.fm/Bjc3R).

The manufacturing operating agreement expands the production capabilities of Lexaria’s growing list of business-to-business clientele interested in purchasing DehydraTECH-powered active ingredients for packaged-goods brands. The new, state-of-the-art processing facility built by BevNology is…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Reach of its Drug Delivery Technology Through Newly Inked Agreements with Beverage Developer BevNology

June 27, 2022

June 27, 2022 09:35:00

Drug delivery technology innovator Lexaria Bioscience has developed a patented technology showing superiority in animal and human testing as a means of improving existing drug brands’ performance and establishing new solutions for unmet medical needs
The company recently announced agreements with beverage developer BevNology to expand production capabilities for Lexaria’s own growing list of B2B clientele and empowering BevNology to offer DehydraTECH products with active ingredients derived from hemp including CBD under BevNology and partnered brands
The technology is called DehydraTECH — improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery
Lexaria also recently announced an agreement with Ireland’s Anodgen Bioceuticals that allows Anodgen to manufacture and distribute DehydraTECH processed cannabinoid API powders within Europe including the UK, Australia and New Zealand

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has built the reputation of its patented DehydraTECH drug delivery technology through a growing data set of potential medicinal applications and through an expanding list of licensing agreements with third-party companies interested in its potential for cannabidiol (“CBD”)-based products.

Lexaria’s patented DehydraTECH technology transforms a wide variety of orally and topically administered products into enhanced solutions that make the APIs more rapidly available and effective at…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grants Licenses to Three Companies for the Month of June; Looks to Follow Through with its Scheduled 2022 Clinical Studies

June 23, 2022

June 23, 2022 08:05:00

Lexaria sold Premier Wellness Science Co. exclusive rights to use its patented DehyraTECH(TM) in Japan in a variety of CBD products
Valcon Medical A/S also signed an agreement with Lexaria to use its platform for medical cannabis applications in Europe
AnodGen Bioceuticals received a pharmaceutical license to use the platform for manufacturing and distributing CBD API powders in Europe, Australia, and New Zealand

Lexaria Bioscience (NASDAQ: LEXX) kicked off the month by announcing an exclusive license to Premier Wellness Science Co. for the use of its patented DehydraTECH(TM) technology in Japan in a variety of CBD products. Announced on June 3, this license would cover oral or non-liquid products and can be used in topical, hair-care, lip-care, and cosmetics segments.

Premier is a wholesale and retail marketer of cosmetics and health foods in Japan. It also provides information and consulting services to entities in the anti-aging, beauty, and health industries. In addition, Premier also offers market research, data collection, and analysis for its…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Expanding Array of API Enhancements Through Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented Drug Technology Bodes Well for New Patient Solutions

June 21, 2022

June 21, 2022 08:50:00

Drug bioavailability enhancement technology developer Lexaria Bioscience is working to increase the number of potential new solutions to unmet medical needs and improving existing treatments for other chronic conditions
Lexaria’s patented DehydraTECH solution transforms a wide variety of orally and topically administered products into enhanced solutions that make the active pharmaceutical ingredients (“APIs”) more rapidly available and effective at lower doses
DehydraTECH-enhanced products have also demonstrated the ability to cross the blood-brain barrier through fatty acid transport proteins
The company’s ongoing series of tests of different DehydraTECH-enhanced products has led to a pre-IND filing with the FDA for a prospective registered treatment for hypertension, while other anticipated potential therapies target seizures, nicotine addiction and erectile dysfunction

The COVID pandemic that roiled the world’s healthcare systems during the past two years (and appears to be hospitalizing an increasing number of patients again (https://cnw.fm/iEIXl) revealed a marked demand for repurposing existing drugs for unanticipated treatments, particularly prior to the provisional development of various targeted vaccines to combat the novel coronavirus (https://cnw.fm/cnOfh).

New data analysis has revealed the potential for several existing biopharma products to be repositioned to treat patients with unmet medical needs, potentially opening the way for dozens of new solutions to…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Achieves Key Milestone in Global Expansion Plan with JustCBD Launch on Amazon UK

June 17, 2022

June 17, 2022 08:05:00

Flora Growth completed the acquisition of Just Brands LLC and High Roller Private Label LLC, owners of the JustCBD brand, on February 28, 2022
The company then expanded its operational footprint in Europe and the UK in May 2022 to further its international growth strategy
JustCBD products, including gummies and tinctures, will be available on www.Amazon.co.uk starting this month in a pilot-only program
Flora Growth is optimistic that this launch will allow the company to reach a larger consumer base as it works towards further expanding its operations across Europe

On February 28, 2022, Flora Growth (NASDAQ: FLGC) completed the acquisition of 100% equity interests of Just Brands LLC and High Roller Private Label LLC, owners of the JustCBD brand. The transaction, which involved a consideration of $16 million in cash and 9.5 million in privately issued Flora common shares, was a move by Flora Growth to explore global expansion opportunities and increase the company’s customer database (https://cnw.fm/ccydT).

By mid-May 2022, Flora Growth had already announced the expansion of its operational footprint in Europe and the United Kingdom to further its international growth strategy. But, more importantly, the move signaled the company’s assertive push to broaden the reach for its JustCBD’s…

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Initiates Communication with the FDA Concerning Potential Treatment for Hypertension; Out-Licenses Its DehydraTECH Technology to International Markets

June 15, 2022

June 15, 2022 09:35:00

Lexaria, a global innovator of drug delivery platforms, recently filed a pre-IND meeting request letter with the FDA, initiating communication regarding the development of its DehydraTECH-CBD as a treatment for hypertension
The company has been undertaking preparatory programs in readiness for the meeting, as well as an IND application filing
The pre-IND meeting will confirm the details of the company’s IND-enabling program
Lexaria also announced it had licensed its DehydraTECH technology to AnodGen, with the announcement following similar out-licensing agreements with Valcon Medical and Premier Science

Early last September, global innovator Lexaria Bioscience (NASDAQ: LEXX) was pleased to announce it had formally commenced the process toward an Investigational New Drug (“IND”) application filing with the Food and Drug Administration (“FDA”) with its DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of hypertension (https://cnw.fm/rDcfI).

According to the September 8 news release, Lexaria had retained the services of an expert regulatory affairs and quality assurance consulting group that would help prepare the company for a pre-IND meeting with the FDA. The group would also assist Lexaria with designing the requisite…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Adding to Cannabis Product Line, Research

June 8, 2022

June 8, 2022 08:50:00

Flora Growth is building on its cannabis brand globalization efforts with two partnerships that expand its product portfolio and its research efforts in the United States and United Kingdom
Flora’s partnership with former NFL athlete Ricky Williams has delivered its first product — a cannabis one-hitter accessory designed to provide a unique experience emblematic of Williams’ active lifestyle brand
The company’s acquisition of the Masaya CBD brand developed by a cell biologist on Flora’s board of directors gives the company a formulation suitable for its current clinical trial efforts in the United Kingdom, and a well-received brand designed to help seizure patients
Flora’s cultivation operations are centered at its Colombia facility, and recent regulatory changes there have made it easier for Flora to supply its brands in the United States and elsewhere

On the heels of a year in which global cannabis market brand-builder Flora Growth (NASDAQ: FLGC) saw rapid expansion of its cultivation, manufacturing and distribution operations that support the company’s business divisions for cosmetics, hemp textiles and food and beverage products, Flora is increasing its offerings by bringing a promising CBD brand into its fold and introducing a new product for quality cannabis experiences.

The acquisition of cell biologist Dr. Annabelle Manalo-Morgan’s Masaya brand gives Flora Growth its first offering under its Flora Life Sciences division as well as a patent-pending formulation for use in Flora’s…

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Mines Potential of Helping Medicines Do What they Do, But Better

June 3, 2022

June 3, 2022 08:05:00

Lexaria Bioscience is a global innovator in drug delivery platforms, developing a technology designed to improve the performance of other medicinal products by making them more rapidly and effectively usable by patients’ bodies
Lexaria’s patented DehydraTECH technology has been studied in combination with a number of other products, including but not limited to, cannabidiol (“CBD”), oral nicotine, antivirals, NSAIDs, and erectile dysfunction therapies
The company is pursuing FDA approval under the Investigational New Drug (“IND”) process to clinically test its DehydraTECH-CBD for the treatment of high blood pressure
A driving focus of the company’s R&D has been to improve the speed of onset, increase bioavailability and brain absorption of active pharmaceutical ingredients

A common refrain in the world of advertising medicinal substances is that a select product can enhance a patient’s ability to live an active life despite debilitating medical conditions.

“By helping to control eczema with Dupixent you can show more (skin),” one prominent ad message declared in recent months, while another offered examples of hope by testifying, “Opdivo plus Yervoy…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.